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ABSTRACT 
 
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system 
that act as first-line defenders against intracellular pathogens. Their functions are 
dictated by germline-encoded activating and inhibitory receptors, of which the most 
diverse family is the killer-cell immunoglobulin-like receptors (KIRs). Whereas many 
KIRs bind well-described HLA class I (HLA-I) ligands, many remain “orphaned” despite 
robust disease associations. KIR3DS1, in particular, is an activating receptor that has 
been associated to delayed HIV-1 disease progression, as well as the outcome of 
several other human diseases. However, despite knowing the ligands of its highly 
homologous inhibitory counterpart KIR3DL1, a ligand that accounts for the biological 
effects of KIR3DS1 remained unknown. 
To identify HLA-I ligands of KIR3DS1, we screened 100 HLA-I proteins and 
found that KIR3DS1 binds HLA-F, which was validated biochemically and functionally. 
Primary human KIR3DS1+ NK cells exhibited a polyfunctional response upon 
encountering HLA-F, and suppressed HIV-1 replication in vitro. Next, we probed the 
cellular contexts for HLA-F expression, and found that CD4+ T-cell activation induced 
HLA-F expression and binding of soluble KIR3DS1-Fc. Although HLA-F was expressed 
intracellularly in transduced cell lines, HLA-F mobilization to the cell surface could be 
iii 
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achieved by cellular activation and inflammatory cytokines, suggesting that HLA-F is 
expressed in the context of inflammation. 
To ascertain non–HLA-I ligands of KIR3DS1, we found that cell lines of various 
tissue origins bound KIR3DS1-Fc irrespective of HLA-F expression. Using a genome-
wide CRISPR/Cas9 knock-out screen, we discovered that KIR3DS1 bound to heparan 
sulfate proteoglycans (HSPGs), which was validated biochemically and using cell lines 
and primary cells. In addition, given the previously assumed binding of KIR3DS1 to 
HLA-B*57:01, as well as the well-document binding of KIR3DL1 to HLA-B*57:01, we 
investigated these interactions and found that binding of KIR3DL1 to HLA-B*57:01 is N-
glycan dependent, which has not been previously described and may play a modulatory 
role in KIR:HLA-I interactions. 
Thus, we established HLA-F and HSPGs as ligands of KIR3DS1, demonstrated 
cell-context–dependent expression of HLA-F and HSPGs, and revealed dependency of 
the HLA-I N-glycan in KIR:HLA-I interactions that may explain the widespread influence 
of KIR3DS1 and other NK-cell receptors in human diseases. 
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CHAPTER 1: Introduction 
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1.1 Natural killer cells and their receptor families 
In spite of their undeserving origins as ‘unspecific assassins,’ natural killer (NK) 
cells are proving to bear increasingly recognized roles in innate and adaptive immune 
responses, adopting characteristics of both arms of the immune system. These innate 
cytotoxic lymphocytes are most notoriously known for killing HLA class I-deficient cells 
and exerting antibody-dependent cell-mediated cytotoxicity (ADCC). However, their 
variegated expression of highly diverse germline-encoded activating and inhibitory 
receptors bestows upon them the ability to act as a multi-specific, poly-functional army 
of first-line defenders against intracellular pathogens as part of their many crucial 
functions.  
The major classes of NK-cell receptors are depicted in Illustration 1.11, all of 
which allow NK cells to discriminate between healthy “self” and a variety of pathological 
cell states, including “missing self,” “altered/stress-induced self,” and “infectious non-
self.”2 Of these, the most diverse family is the killer-cell immunoglobulin (Ig)-like 
receptors (KIRs), exhibiting the most polymorphisms in the entire human genome 
secondary only to the major histocompatibility complex (MHC)3. The KIR locus encodes 
for a plethora of activating and inhibitory receptors that bind to HLA class Ia and Ib 
molecules with variable specificity. 
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Illustration 1.1: NK-cell receptors and ligands 
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1.2 Overview of the KIR family 
KIR family receptors are categorized by the number of Ig-like extracellular 
domains (2D or 3D) they contain and by whether they have a long (L) or short (S) 
cytoplasmic tail. Overall, KIR2D molecules bind HLA-C ligands, whereas KIR3D 
molecules bind HLA-A and -B ligands4, although there are many exceptions. KIR-L 
molecules are inhibitory, as they have long immune tyrosine inhibitory motif (ITIM)-
bearing cytoplasmic tails. KIR-S molecules, on the other hand, have a truncated 
cytoplasmic tail and possess a positively-charged residue in their transmembrane 
domain that allows association to immune tyrosine activating motif (ITAM)-bearing 
adaptor molecules such as DAP125 (for detailed information about KIRs used in this 
body of work, see Illustration 1.2). Although KIR binding to HLA ligands was previously 
deemed non–peptide-specific, an increasing amount of studies have discovered 
exquisite peptide sensitivity in this interaction6,7, a finding that has only begun to be 
appreciated. 
 
Illustration 1.2: Schematic of the structure, signaling, and ligands of KIRs studied. 
D0
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? HLA-Bw4
KIR3DS1 KIR3DL1
Ligands
KIR3DL2KIR2D
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ITIM
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ITAM
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ITIM
ITIM
S
L
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Structure
Signaling
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The high polymorphicity of both KIR and HLA genes highlights a deep-seated 
evolutionary interplay of receptor:ligand pairs driven by forces of reproduction and 
infectious disease survival3. However, the role KIR:HLA interactions play in dictating 
NK-cell function has been continually shown to be crucial in five major areas of 
human health and disease: cancer, transplantation, autoimmunity, reproduction, and 
infectious diseases. In the realm of infectious diseases, control of viral pathogen and 
intracellular bacteria is an essential NK-cell function necessary for host survival, as 
exemplified by the rare of cases of human NK-cell deficiency that result in death in 
early life8, but of particular interest to us was the well-documented role of NK cells 
and their receptors in HIV-1 infection. 
 
1.3 Previously unrecognized role of NK cells in immune responses to HIV-1 
HIV-1 first arose in Africa as a cross-species transmission event from simian 
immunodefiency virus (SIV) in the 1930s9. As such, there has been no time for human 
evolution to take place and establish a ‘truce’ between host and pathogen, as occurred 
for other viral infections (e.g. herpes viruses). Today it affects 36.9 million adults and 
children worldwide and in 2014 alone led to 2 million new infections and 1.2 million 
deaths10. Amidst our efforts to combat HIV/AIDS, however, a great deal has been 
learned about the immune system and how this virus has been able to cripple it. HIV 
immunology and virology research has largely focused on understanding the HIV life 
cycle, elucidating virion structure, aiding anti-retroviral drug and vaccine development, 
and characterizing cellular and humoral immune responses throughout infection. 
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Illustration 1.3: Immune response to HIV-1 (published in 11)  
 
The interplay between HIV-1 and the human immune response is one of rapid 
micro-evolution12. The virus employs an armamentarium of immune evasion strategies, 
the most significant being its extraordinary ability to rapidly mutate and escape 
recognition by the immune system. Immune pressure driving escape arises from 
exhuberant anti-viral CD8+ T cell responses targeting HLA-presented viral epitopes as 
well as B-cell antibody responses that attempt to neutralize HIV envelope protein (see 
Illustration 1.3, diagram published in 11). However, one previously unexpected source 
of immune control and immune pressure is NK cells. Studies from our laboratory have 
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shown that NK cells alone mediate viral inhibition in co-cultures with HIV-1–infected 
CD4+ T-cells via in-vitro/ex-vivo assays13. Additionally, we have described the existence 
of ‘KIR footprints’—that is, HIV-1 peptide variants found more commonly in individuals 
bearing a specific KIR—that lead to increased NK cell inhibition and, potentially, 
reduced elimination of HIV-1–infected cells14,15. As a consequence, these innate 
cytotoxic effectors highlight a previously ignored but increasingly important role that NK 
cells and their KIRs play in killing HIV-1–infected cells and influencing HIV-1 acquisition 
and disease progression. 
 
1.4 Association between KIRs and HIV-1 acquisition and disease progression 
The first association between KIRs and HIV-1 was made in an epidemiologic 
study in 2002 by Martin et al.16, where patients possessing both the activating NK-cell 
receptor KIR3DS1 gene and one of various HLA-A or HLA-B alleles with a Bw4 motif 
and an isoleucine at position 80 (HLA-Bw4I80) were found to progress more slowly to 
AIDS, when compared to patients having either or neither alleles. KIR3DS1 is a 
functionally divergent allele of the KIR3DL1/S1 gene, a unique KIR gene locus in that it 
contains both inhibitory KIR3DL1 alleles and activating KIR3DS1 alleles3. KIR3DL1 had 
previously been shown to bind HLA-Bw4 allotypes with sensitivity to polymorphisms in 
position 8017, but this epistatic association between KIR3DS1 and HLA-B in HIV-1 
disease progression seemed to have uncovered a new KIR:HLA interaction. More 
importantly, this was the first time an association had ever been made between a KIR 
and a viral infection. This opened the path for a multitude of investigators to seek out 
and dissect further associations between KIR3DL1/S1 and HIV-1 infection. 
 8 
Additional findings showed that individuals possessing particular KIR3DL1 alleles 
and HLA-Bw4 progressed more slowly to AIDS when compared to individuals without 
HLA-Bw418.Furthermore, it appeared that the protective effect with HLA-Bw4 was most 
prominent in a KIR3DL1/S1 heterozygous state19. Additionally, two studies20,21 found a 
significant overrepresentation of KIR3DS1 in HIV-1-exposed seronegative individuals 
that possessed HLA-Bw4 allotypes. This supported the notion that although both 
KIR3DL1 and KIR3DS1 protected from HIV-1 disease progression in patients bearing 
HLA-Bw4 allotypes, KIR3DS1 also protected against HIV-1 acquisition. This finding 
paralleled a study which observed a protective effect against HIV-1 acquisition in HIV-
1–discordant couples that were KIR:HLA mismatched for KIR2DL1/L3 and HLA-C2/C1 
ligands22. These findings are in agreement with the known functions of KIRs in NK cells, 
one of which is to mediate licensing. Licensing is a tolerance-ensuring phenomenon in 
which NK cells acquire the ability to kill target cells deficient in a specific HLA ligand 
only after having that HLA ligand engage an inhibitory KIR during development23. For 
example, Martin et al.’s study18 supports the idea that KIR3DL1+ NK cells licensed by 
HLA-Bw4 killed HIV-1–infected CD4+ T cells undergoing Nef-induced downregulation of 
HLA-A and -B, whereas Jennes et al.22 proposed that KIR2DL1+ NK cells licensed by 
HLA-C2 killed transmitted HIV-1–infected CD4+ T cells lacking the appropriate HLA-C 
ligands. However, research attempting to characterize and dissect the protective effect 
of KIR3DS1 in HIV-1 has yielded mixed results, despite it being the first described KIR–
virus association. 
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1.5 A definite but mechanistically controversial role for KIR3DS1 in HIV-1 infection 
The major reason for controversy over the mechanism by which KIR3DS1 
confers protection in HIV-1 infection is because there was no proven ligand. 
Epidemiologic and functional studies have provided circumstantial evidence implicating 
HLA-Bw4I80 as a likely ligand, but efforts to establish this interaction using techniques 
used to identify KIR3DL1 ligands failed to do so. Even in light of the published crystal 
structure of self-peptide:HLA-B*57:01 bound to KIR3DL1*00124, a prototypical allotype 
of KIR3DL1 that has 97.5% protein sequence homology to the most common allotype of 
KIR3DS1 (*013) in its extracellular domain, no significant advances were made. The 
only exception is a single recent study that demonstrated KIR3DS1 binding to HLA-
B*57:01 refolded around two HIV-1 peptides that arose from an exhaustive screen of 
various self and viral peptide databases25. However, it is not clear whether this 
interaction has real functional consequences, or represents an exceptional case where 
a peptide can overcome KIR3DS1 mutations that normally abrogate HLA-Bw4 binding. 
Thus far, investigations attempting to elucidate the ligand have done so through 
cellular immunology, functional studies, and cohort analyses, the results of which are 
not always in agreement. Increased frequencies of KIR3DS1+ NK cells have been 
reported in HLA-Bw4I80–positive individuals when compared to HLA-Bw4–negative 
individuals26. Also, KIR3DS1+ NK cells specifically expanded in acute HIV-1 infection 
and persisted throughout chronic infection in HLA-Bw4I80–positive versus HLA-Bw4–
negative individuals27. Indeed, many studies have cogently demonstrated the ability of 
KIR3DS1+ NK cells, but not KIR3DL1+ NK cells, to effectively inhibit HIV-1 viral 
replication in co-culture with autologous HIV-1–infected CD4+ T cells from HLA-Bw4I80–
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positive individuals13,28. However, a study by Long et al.29 revealed that while KIR3DS1 
positivity correlated with increased CD107a and IFN-γ expression by bulk NK cells in 
acute HIV-1 infection, there was no association to the co-presence of HLA-Bw4I80. 
Morvan et al.26 also described a preferential expansion of KIR3DS1+ NK cells in 
response to various non-specific stimuli such as HLA-deficient targets, interleukin 
treatment, and Toll-like receptor agonists, but found that these cells responded 
indiscriminately to HLA-Bw4 and HLA-Bw6–transduced cells. One controversial study 
by Barbour et al.30 analyzed a cohort of 255 HIV-1–infected individuals and showed that 
KIR3DS1 and HLA-Bw4I80 were independently associated with higher CD4+ T cells 
counts and lower viral loads, respectively, when compared to subjects without these 
allotypes, thus contesting the argument of synergy and favoring a phenomenon of 
additive independence between KIR3DS1 and HLA-Bw4I80. Overall, investigators have 
been limited in proving a direct interaction between KIR3DS1 and any ligand, leaving a 
gap in our understanding of KIR3DS1 biology. 
 
1.6 The need to discover the ligand for KIR3DS1 
It has been over a decade since the first association between KIR and a viral 
infection was made between KIR3DS1 and HIV-1 disease progression, and yet there 
has been no ligand discovered to understand the underlying mechanism of this 
phenomenon. Since then, numerous associations between KIR3DS1 and various 
clinical outcomes have arisen—highlighted in Table 1.131–42—but with no known 
mechanism for further study. As there is compelling evidence that NK cells and their 
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receptors play a major role in anti-viral and anti-tumor immunity not only in their innate 
immune  functions  but  also  in  their  ability  to  act  as  ‘rheostats’  to  adaptive immune  
Viral 
Infections 
↓ HIV-1 disease progression (HLA-Bw4I80+) 
↑ spontaneous recovery from hepatitis B infection 
↑ severe pandemic H1N1 influenza A infections 
↑ HCV clearance after treatment in HIV/HCV co-infection (HLA-Bw4+) 
↓ BK virus infection/nephropathy after kidney transplant 
Malignancies 
↓ HCV-related hepatocellular carcinoma (HLA-Bw4I80+) 
↓ Hodgkin’s lymphoma 
↓ respiratory papillomatosis 
↑ risk of cervical neoplasia 
BMT/HSCT 
↓ progression-free survival in multiple myeloma (autologous) 
↓ acute GvHD (donor allogeneic) 
↓ overall survival (HLA-Bw4–) 
Autoimmunity ↑ susceptibility to ankylosing spondylitis (HLA-B27+) 
 
Table 1.1 Disease associations when KIR3DS1 is present 
 
responses43,44 and adopt characteristics such as antigen specificity and possibly 
memory45, it is imperative that the elusive KIR3DS1 ligand be found. The implications of 
finding such ligand and unraveling KIR3DS1 biology would offer potential new targets to 
manipulate in future preventative and therapeutic HIV-1 vaccine strategies and bolster 
the use of NK-cell-receptor–directed immunotherapeutics, as has already been done in 
a phase I clinical trial targeting KIR2DLs in multiple myeloma patients46. Consequently, 
the goal of this work was to discover the ligand of KIR3DS1 by designing and 
employing unbiased biochemical, molecular biological, and cellular 
immunological strategies, in the hopes of elucidating the mechanism by which 
KIR3DS1 confers protection in HIV-1 infection and alters the course of other 
human diseases. 
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 Undertaking this endeavor, multiple lines of investigation arose concerning other 
NK-cell receptors, particularly KIRs, and their ligands. In Chapter 2 and Chapter 3, the 
discovery and biological implications of HLA-F binding to KIR3DS1 are explored, with a 
summary of background information between presented in the section 2.1 Background. 
In Chapter 4, heparan sulfate proteoglycans are described as ligands for KIR3DS1 and 
other NK-cell receptors; information concerning NK-cell receptor:carbohydrate 
interactions and heparan sulfate biology can be found in the section 4.1 Background. 
In Chapter 5, where HLA-I N-glycosylation is studied and manipulated in the context of 
KIR:HLA-I binding, information regarding HLA-I N-glycans can be found in the section 
5.1 Background section. Conclusions and discussion of the implications of all each of 
these findings are discussed in Chapter 6 (Discussion). 
  
 
 
 
 
 
 
 
CHAPTER 2: Open conformers of HLA-F are high-affinity ligands of the 
activating NK-cell receptor KIR3DS1 
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2.1 SUMMARY 
The activating NK-cell receptor KIR3DS1 has been implicated in the outcome of 
various human diseases, including delayed HIV-1 disease progression, yet for over a 
decade, a ligand that accounts for its biological effects remained unknown. We 
screened 100 classical and non-classical HLA-I proteins as complexes and open 
conformers (OCs) and found that KIR3DS1—along with its functionally divergent 
allotype KIR3DL1 and the phylogenetically related KIR3DL2—bound to HLA-F OCs. 
KIR-Fc binding to HLA-F OCs was validated by surface plasmon resonance, which 
showed the highest affinity binding between KIR3DS1 and HLA-F OCs, followed by 
KIR3DL2 and KIR3DL1. These interactions were assessed at the cellular level using 
Jurkat cells stably expressing KIR-CD3ζ chimeric receptors. These confirmed that 
KIR3DS1 strongly signaled upon engagement of HLA-F OCs on target cells, while 
KIR3DL2 and KIR3DL1 also signaled although to a lesser extent. These findings 
establish that HLA-F OCs are functionally relevant, high-affinity ligands of KIR3DS1 and 
open the door to future studies seeking to understand the wide-spread biological roles 
of KIR3DS1 in human disease. 
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2.2 BACKGROUND 
Killer-cell immunoglobulin (Ig)-like receptors (KIRs) are a family of HLA class I-
binding receptors expressed on natural killer (NK) cells that are implicated in various 
areas of human health and disease. The KIR locus contains some of the most highly 
polymorphic human genes, a diversity comparable to HLA genes in the major 
histocompatibility complex (MHC) locus3. This highlights a deep-seated evolutionary 
interplay of receptor:ligand pairs driven mainly by forces of reproduction and infectious 
disease survival3. Through variegated expression of KIRs and other highly diverse 
germline-encoded receptors, NK cells are able to discriminate between healthy “self” 
and a variety of pathological cell states2. As such, it is unsurprising that NK cells and 
KIRs have a broad involvement in human disease47, especially in light of their 
increasingly recognized roles in innate and adaptive immune responses43,48. 
KIR family receptors are categorized by the number of Ig-like extracellular 
domains they contain (2D or 3D) and by whether they have a long (L) or short (S) 
cytoplasmic tail. KIR-L receptors are inhibitory, as they have immune tyrosine inhibitory 
motif (ITIM)-bearing cytoplasmic tails, whereas KIR-S receptors have truncated 
cytoplasmic tails and possess a transmembrane positive charge that allows association 
to immune tyrosine activating motif (ITAM)-bearing adaptor molecules such as DAP12. 
In general, KIR2D receptors bind HLA-C, whereas KIR3D receptors bind HLA-A and -B. 
Nevertheless, while many HLA class I (HLA-I) ligands have been identified for multiple 
KIRs, several have remained more elusive, particularly for activating KIRs. 
KIR3DS1 was the first KIR to be associated with the outcome of a viral infection, 
namely, delayed human immunodeficiency virus (HIV)-1 disease progression in patients 
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with certain HLA-B alleles16. Since then, it has been linked to other viral 
infections16,19,31,42,49, autoimmune disorders41, cancer development/clearance33,34,36,37, 
and transplantation outcomes38–40, and therefore has become one of the most studied 
KIRs. KIR3DS1 is an activating receptor that stimulates cytotoxicity and IFN-γ 
production in NK cells5. It is encoded in the KIR3DL1/S1 gene locus, a unique KIR locus 
because it encodes for functionally divergent alleles3. Remarkably, while sharing >95% 
homology in their extracellular domain, KIR3DS1 and its inhibitory counterpart KIR3DL1 
have different ligand binding profiles. KIR3DL1 has conclusively been shown to bind 
HLA-A and -B allotypes with a Bw4 motif, with variable sensitivity to C-terminal residues 
of HLA-Bw4-bound peptides and to residues at position 80 of HLA-I17. However, 
attempts to identify a KIR3DS1 ligand by various groups have repeatedly failed50,51, 
save for a single recent study demonstrating peptide-dependent binding of KIR3DS1 to 
HLA-B*57:01 in vitro25. Both KIR3DL1 and KIR3DS1 have been strongly linked to HLA-
Bw4 allotypes in disease association studies, including HIV-1 pathogenesis16,18, but 
direct KIR3DS1:HLA-Bw4 interactions are a major point of controversy. Indeed, some 
studies report an independence between KIR3DS1 and HLA-Bw429,30. Furthermore, 
even in studies linking KIR3DS1 and HLA-Bw4, the vast majority of KIR3DS1+ subjects 
also possessed KIR3DL1, imposing a confounding variable since KIR3DL1 binds HLA-
Bw4 proteins. Of note, while KIR3DL1 exhibits significant sequence polymorphisms that 
have been shown to alter KIR3DL1 protein surface expression52 and ligand binding53,54, 
KIR3DS1 is remarkably conserved and virtually monomorphic. This is despite KIR3DS1 
having arisen in the human genome >3 million years ago along with various alleles of 
KIR3DL1, and being present in almost all human populations worldwide3.  
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2.3 RESULTS 
2.3.1 Comprehensive HLA-I screening shows that KIR3DS1 binds to HLA-F OCs 
We aimed to systematically assess KIR3DS1 binding to a panel of HLA-I proteins 
in two biologically relevant conformation states: as HLA-I complexes, which are folded 
heavy chains bound to β2-microglobulin (β2m) and peptide, and as HLA-I open 
conformers (OCs), which are HLA-I heavy chains without bound β2m or peptide 
(reviewed in 55). To accomplish this, we tested binding of soluble KIR3DS1-Fc and other 
KIR-Fc fusion constructs to HLA-I-coated beads individually bearing 97 allotypes of 
classical HLA-I (i.e. HLA-A, -B, and -C) that were either untreated or acid pulsed. Acid 
pulsing is a well-established method of stripping away β2m and HLA-I-bound peptides to 
rapidly generate HLA-I OCs. KIR3DS1-Fc did not bind appreciably to any classical HLA-
I alleles tested either as complexes (untreated) or OCs (acid pulsed) (Fig. 2.1a). 
However, KIR3DL1-Fc bound preferentially to HLA-Bw4 complexes, and KIR2DL3-Fc 
and KIR2DS4-Fc bound to HLA-C complexes (Fig. 2.1a), as expected. KIR3DL2-Fc did 
not have any preferential binding to specific HLA-I proteins. Of note, HLA-I complexes 
on these beads presented a diverse repertoire of peptides derived from the human cell 
line the HLA-I proteins were produced in, which precludes any peptide specificity 
analysis. Thus, KIR3DS1 does not bind to classical HLA-I complexes (presenting a 
diverse immunopeptidome) or HLA-I OCs. 
 
 18 
 
 
Figure 2.1: KIR-Fc binding to beads coated with classical and non-classical HLA-I proteins. (a) 
HLA-I-coated beads (from One Lambda) were untreated or acid pulsed and stained with the indicated 
KIR-Fc constructs (200 μg/mL each) to assess binding to complexes (untreated) versus open conformers 
(acid treated) of each classical HLA-I gene allotype; negative control beads (red star) were used to 
assess background staining. For KIR3DL1-Fc and KIR3DS1-Fc, similar results were achieved with two 
other KIR-Fc concentrations (100 μg/mL and 20 μg/mL) done in parallel and also when repeated 
independently with a flow cytometry-based HLA-I-coated bead kit (data not shown). (b) HLA-E, -F, and -
G-coated beads (generated in this study) were untreated or acid pulsed and stained with the indicated 
KIR-Fc constructs (25 μg/mL each). Negative control beads (neg. control) were used to assess 
background staining; ‘HLA-F (OC)’ denotes HLA-F in open conformation on both untreated and acid-
pulsed beads. 
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Because non-classical HLA-I proteins (i.e. HLA-E, -F, and -G) were not included 
in the original HLA-I-coated bead panel, we separately produced these. We coated 
streptavidin-beads with biotinylated HLA-E, -F, or -G monomers refolded around β2m 
and peptide (no peptide in the case of HLA-F given that it does not present peptide56; 
details in Materials and Methods). In order to confirm that HLA-I proteins were in 
complex conformation after loading them onto beads, we assessed anti-pan-HLA-I 
complex (clone: W6/32) antibody binding to HLA-I-coated beads before and after acid 
pulsing by flow cytometry; this antibody can recognize all HLA-A, -B, -C, -E, -F, and -G 
proteins but only when they are bound to β2m. As expected, all acid-pulsed beads did 
not bind anti-pan-HLA-I complex antibody due to stripping of β2m (Supplementary Fig. 
S2.1a). However, we found that for untreated beads, while HLA-E and -G readily bound 
anti-pan-HLA-I complex antibody, HLA-F did not (Supplementary Fig. S2.1a). We 
assessed β2m content on the untreated HLA-I-coated beads by anti-β2m antibody 
staining, and found that HLA-F-coated beads had ~60% less β2m content than HLA-E- 
and HLA-G-coated beads (Supplementary Fig. S2.1b). This indicated that unlike other 
HLA-I proteins, HLA-F readily dissociates from β2m and spontaneously forms HLA-F 
OCs on artificial surfaces, which is in line with its unique property of being stable as an 
open conformer57. 
Upon testing KIR-Fc binding to non-classical HLA-I-coated beads, we found that 
KIR3DS1-Fc strongly bound to HLA-F-coated beads; this was independent of acid 
treatment, consistent with the fact that both untreated and acid-pulsed beads contained 
HLA-F OCs (Fig. 2.1b and Fig. 2.2). KIR3DL1-Fc and KIR3DL2-Fc were similarly able 
to bind HLA-F-coated beads (both acid pulsed and untreated); however, KIR2DL3-Fc 
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and KIR2DS4-Fc did not bind to any non-classical HLA-I-coated beads (Fig. 2.1b). 
Consequently, we determined from this assay that KIR3DS1, along with its functionally 
divergent allotype KIR3DL1 and the phylogenetically related KIR3DL23, bind HLA-F 
OCs. 
 
 
2.3.2 Surface plasmon resonance confirms KIR3DS1 binding to HLA-F OCs 
To confirm our findings, we performed surface plasmon resonance to 
quantitatively assess the affinities between HLA-F OCs and various KIRs. KIR3DS1 had 
the highest affinity to HLA-F OCs of the tested KIRs (KD = (25 ± 1) nM), followed by 
KIR3DL2 (KD = (118 ± 1) nM) and KIR3DL1 (KD = (157 ± 2) nM), while KIR2DS4 and 
KIR2DL3-Fc did not exhibit any binding even at the highest tested concentrations (Fig. 
2.3 and Table 2.1). The kinetic data showed that the affinity of KIR3DS1 to HLA-F OCs 
is mainly driven by a relatively small dissociation rate (kd = (7.0 ± 0.3) × 10–4 s–1) as 
compared to KIR3DL1 (kd = (6.91 ± 0.09) × 10–3 s–1) and KIR3DL2 (kd = (5.08 ± 0.04) × 
10–3 s–1), reflecting a higher stability of the interaction once formed. Together, these 
data demonstrated that all ‘lineage II KIRs’ (i.e. KIR3DL1, KIR3DS1, and KIR3DL2) can 
bind HLA-F OCs, although with varying affinities and in a manner that is opposite to that 
(-)
E
F
G
KIR3DS1-Fc
Figure 2.2: KIR3DS1-Fc binding to beads coated with non-
classical HLA-I proteins. Flow cytometry histograms showing results 
for binding of KIR3DS1-Fc (25 μg/mL) to untreated non-classical HLA-
I-coated beads; ‘(-)’ denotes negative control beads, and ‘E’, ‘F’, and 
‘G’ denote HLA-E-, -F-, and -G-coated beads, respectively. 
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involving binding to classical HLA-I molecules, where inhibitory KIRs normally bind with 
significantly higher affinity. 
 
Figure 2.3: Surface plasmon resonance of KIR-Fc binding to HLA-F OCs. Each panel represents flow 
sensograms of the indicated KIR-Fc constructs at the indicated concentrations flowed over a flow cell with 
approximately 1000 response units of immobilized HLA-F OCs. Colored lines legends apply for all 
graphs. Similar results were achieved in two independent experiments (data not shown). 
 
Constant ka (M–1s–1) (×104) kd (s–1) (×10–4) KD (nM) 
KIR3DL1 4.40 ± 0.04 69.1 ± 0.9 157 ± 2 
KIR3DS1 2.84 ± 0.02 7.0 ± 0.3 25 ± 1 
KIR3DL2 4.30 ± 0.02 50.8 ± 0.4 118 ± 1 
KIR2DL3 –* –* –* 
KIR2DS4 –* –* –* 
 
Table 2.1: Kinetic values of KIR binding to HLA-F OCs as determined by surface plasmon 
resonance. All values represent monomeric interaction kinetic values calculated from the ‘bivalent 
analyte’ fitting model on BIAevaluation software and are presented as mean ± standard error of the mean. 
Asterisk (*) indicates there was no binding detected at highest tested concentration (0.5 μM) of KIR-Fc. 
Kinetic constants: ka, association rate constant (a.k.a. on-rate); kd, dissociation rate constant (a.k.a. off-
rate); KD, equilibrium dissociation constant. 
 
 
2.3.3 Functional activation of KIR3DS1ζ Jurkat reporter cells is triggered by 
target cells expressing HLA-F OCs 
To determine whether cell-expressed KIR3DS1 can bind to and be activated by 
HLA-F OC-expressing target cells, we developed a reporter cell assay using Jurkat 
cells. Jurkat cells are a human CD4+ T-cell leukemia line that is HLA-F- and -G-deficient 
and  does  not  have  HLA-Bw4.  We  furthermore  performed  CRISPR/Cas9-mediated 
KIR3DL1-Fc KIR3DS1-Fc KIR3DL2-FcKIR2Ds-Fc
BCL
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Figure 2.4: Generation of KIRζ Jurkat reporter cell lines. (a) KIRζ chimeric receptors for inhibitory and 
activating KIRs were designed by fusing the extracellular domain (ECD) and transmembrane domain 
(TMD) of the indicated KIRs with the triple immune tyrosine activating motif (ITAM)-containing cytoplasmic 
tail (CYT) of CD3ζ. (b) KIRζ-Jurkat reporter cell lines were labelled with fluorescent membrane dyes to 
allow for distinction and anti-KIR antibody staining was done for confirmation of KIR expression. PKH26 
and PKH67 are red and green fluorescence membrane dyes, respectively; Z27 and DX9 are anti-
KIR3DS1/L1 and anti-KIR3DL1 antibodies, respectively (c) CRISPR/Cas9-mediated β2m knockout in 
Jurkat cells was confirmed by absent expression of HLA-I as measured by staining with anti-pan-HLA-I 
antibody (clone: W6/32). (d) Jurkat-β2m-KO cells were stably transduced with indicated KIRζ chimeric 
receptors and staining with anti-KIR antibodies was performed to assess KIR expression; DX27, Z27, and 
5.133 are anti-KIR2DL2/L3, anti-KIR3DS1/L1, and anti-KIR3DL2/S1/L1 antibodies, respectively. 
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knock-out of β2m in Jurkat cells to eliminate surface HLA-I expression (Fig. 2.4c) and 
prevent potential self-activation. Jurkat cells were then stably transduced with chimeric 
receptors containing the extracellular and transmembrane domain of the KIR of interest 
and the cytoplasmic domain of CD3ζ, from herein called ‘KIRζ’ (Fig. 2.4a). For 
KIR3DS1, the transmembrane domain of KIR3DL1 was used instead to ensure cell 
surface expression in the absence of its adaptor DAP12, as has been previously 
shown58; we denoted this construct ‘KIR3DS1hiζ’.  Surface expression of KIRζ on Jurkat 
cells was confirmed by staining with the relevant anti-KIR antibodies (Fig. 2.4b and Fig. 
2.4d), and CD69 expression was used as a reporter cell output, which was validated by 
anti-KIR antibody-mediated crosslinking (Fig. 2.5). 
 
Initially, the ability of KIRζ-Jurkat reporter cells to bind to and be triggered by 
HLA-I-coated cell-sized beads was tested, and this assay showed that KIR3DS1ζ-Jurkat 
reporter cells avidly bound to and were potently triggered by HLA-F-coated beads, as 
were KIR3DL2ζ-Jurkat cells and KIR3DL1ζ-Jurkat cells to a much lesser extent (Fig. 
2.6a and Fig. 2.6b). As expected, no binding or triggering by HLA-F-coated beads was 
observed for KIR2DL3ζ-expressing or untransduced Jurkat reporter cells. Next, KIRζ-
Jurkat  reporter  cell  activity  was  tested  against  cell  lines  that were untreated or acid 
Jurkat reporter cell:
untransduced
KIR3DL1ζ
KIR3DS1hiζ
Figure 2.5: Functionality of KIRζ Jurkat reporter cell lines. 
Cell-sized Dynabeads covalently conjugated to anti-KIR3DL1/S1 
(Z27) antibody or irrelevant mouse IgG (mIgG) were used for 
antibody-mediated crosslinking and activation of KIRζ Jurkat 
reporter cells as a functional positive control. 
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Figure 2.6: HLA-F-coated bead binding to and stimulation of KIRζ Jurkat reporter cell lines. 
Streptavidin beads were coated with free biotin (neg. ctrl. beads) or biotinylated HLA-F monomers (HLA-F 
beads), and these were co-incubated with the indicated KIRζ Jurkat reporter cells at a reporter:bead ratio 
of 1:50 for 8 h. The percentage of cells that bound beads (measured as a positive shift in side-scatter) (in 
a) and the reporter cell activity (percentage of cells that highly expressed CD69) (in b) was determined by 
flow cytometry. 
 
pulsed to generate HLA-I OCs at the cell-surface, which was confirmed by anti-HLA-I 
OC  antibody  staining  (Supplemental Fig. S2.2).  721.221  cells  are a highly-mutated 
EBV-transformed B-cell line commonly used as NK-cell targets that are deficient in 
classical HLA-I genes and only express HLA-E and -F (i.e. HLA-A–B–C–E+F+G–). KIRζ-
Jurkat reporter activity against 721.221 cells revealed that acid-pulsed 721.221 cells 
potently stimulated KIR3DS1hiζ-Jurkat cells (Fig. 2.7a), a finding that occurred 
independent of other expressed HLA-I allotypes (Supplemental Fig. S2.3). KIR3DL2ζ- 
and KIR3DL1ζ-Jurkat cells, but not KIR2DL3ζ-Jurkat cells, were also triggered by acid-
pulsed 721.221 cells, but less potently, especially in the case of KIR3DL1ζ-Jurkat cells, 
in line with binding data (Fig. 2.7a). These data indicated that KIR3DS1 (as well as 
KIR3DL2 and to a lesser extent KIR3DL1) binds HLA-F OCs independent of classical 
HLA-I. 
In assessing KIRζ-Jurkat reporter activity to other cell lines, we found that acid-
pulsed EBV-transformed B cell lines (BCLs) derived from HLA-typed patients also 
a         b 
    binding       stimulation 
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stimulated KIR3DS1hiζ-Jurkat cells, while other cell lines not encoding for HLA-F did not 
(i.e. Jurkat, EL-4, K562, and THP-1 cells) (Fig. 2.7a and Supplementary Fig. S2.4). In 
a separate experiment where KIRζ surface expression was accounted for, triggering of 
KIRζ Jurkat reporter cells by acid-pulsed BCLs revealed the highest level of reporter 
activity  by  KIR3DS1hiζ,  followed  by  KIR3DL2ζ  and  then  KIR3DL1ζ (Fig. 2.8), which 
 
Figure 2.7: Functional triggering of KIR3DS1 on reporter cell lines by HLA-F OCs. (a) KIR3DL1ζ 
(second panel), KIR3DS1hiζ (third panel), KIR3DL2ζ (fourth panel), and untransduced (first panel) Jurkat 
reporter cells were co-incubated with untreated (–; black bars) or acid-pulsed (+; gray bars) cell lines (2.5-
h incubation and reporter:target cell ratio of 1:10); reporter activity was measured as the percentage of 
CD69+hi Jurkat reporter cells. Target cell lines used were an HLA-Bw4– donor-derived EBV-transformed 
B-cell line (BCL), 721.221 cells, and Jurkat cells. Data represent pooled data from n = 2 – 4 independent 
experiments. (b) KIR3DL1ζ (green bars), KIR3DS1hiζ (red bars), KIR3DL2ζ (blue bars), and untransduced 
(white bars) Jurkat reporter cells were co-incubated with an untreated HLA-Bw4+ BCL or an acid-pulsed 
HLA-Bw4– BCLs in the presence of anti-KIR or anti-HLA-I antibodies (each at 25 μg/mL) and reporter 
activity was measured. Antibodies used on graph are labeled with antibody clone and target antigen in 
parenthesis, and are the following: Z27, anti-KIR3DL1/S1 antibody; DX9, anti-KIR3DL1 antibody; HC10, 
anti-HLA-B,C OC (indirectly downregulates HLA-F); HC10, anti-HLA-A,G antibody (exhibits reactivity to 
HLA-F); W6/32, anti-pan-HLA-I complex antibody. Data represent n = 3 technical replicates. 
Jurkat reporter cell:
KIR3DL1ζ KIR3DS1hiζ KIR3DL2ζuntransduced
a 
 
 
 
 
 
 
 
 
 
 
b 
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correlated to SPR-determined affinities. These data showed that compared to other 
lineage II KIRs, KIR3DS1 exhibits the most potent functional signaling capacity upon 
engagement of HLA-F OCs on target cells. 
 
To further confirm the interaction between KIR3DS1 and HLA-F OCs, antibody 
blockade experiments were performed. Of note, we did not have a specific anti-HLA-F 
OC blocking antibody at our disposal. Instead, two anti-HLA-I OC antibodies were used: 
HC10, which binds HLA-B, -C, and -E OCs but has been shown to indirectly down-
regulate HLA-F OCs from the cell surface of target cells via endocytosis57, and HCA2, 
which binds HLA-A and -G OCs but we determined exhibits reactivity to HLA-F OCs 
(data not shown). Accordingly, KIR3DS1hiζ Jurkat reporter cell activity induced by acid-
pulsed BCLs could be blocked by anti-KIR3DS1/L1 and both anti-HLA-I OC antibodies, 
but not by anti-KIR3DL1 or anti-pan-HLA-I complex antibodies (Fig. 2.7b). In addition, 
adding soluble KIR3DS1-Fc to block ligands on target cells also abrogated KIR3DS1hiζ 
Jurkat reporter cell activity induced by acid-pulsed BCLs (Fig. 2.9). The results of these 
antibody blockade experiments are consistent with the finding that KIR3DS1 interacts 
with HLA-F OCs. On the other hand, KIR3DL1ζ Jurkat reporter cell activity triggered by 
Jurkat reporter cell:
BCL
alone
Figure 2.8: Comparison of KIRζ Jurkat reporter cell 
functional triggering by HLA-F OC-expressing target 
cells. KIR3DL1ζ (green bars), KIR3DS1hiζ (red bars), 
KIR3DL2ζ (blue bars), and untransduced (white bars) 
Jurkat reporter cells were co-incubated with untreated (-) 
or acid-pulsed (+) HLA-Bw4– BCLs and reporter activity 
was measured. KIRζ expression was tightly controlled 
for when assessing percentage of CD69+hi cells. Data 
represent n = 3 technical replicates. 
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HLA-Bw4I80 expressing BCLs could be blocked by both anti-KIR3DL1 and anti-pan-
HLA-I complex antibodies, but not by either anti-HLA-I open conformer antibody (Fig. 
2.7b). This confirms the well-documented interaction between KIR3DL1 and HLA-
Bw4I80 complexes. Of note, the weak reporter cell activity of KIR3DL1ζ-Jurkat cells 
stimulated by acid-pulsed HLA-Bw4-negative BCLs could be blocked by both anti-
KIR3DL1 and anti-HLA-I open conformer antibodies, but not the anti-pan-HLA-I complex 
antibody (Fig. 2.7b). This further indicated a low-level interaction between KIR3DL1 and 
HLA-F OCs that is functionally much weaker as compared to KIR3DS1, which is 
remarkable in light of their high homology. 
 
 
  
Figure 2.9: Anti-KIR antibody and KIR-Fc blockade of 
KIR3DS1hiζ Jurkat reporter cell triggering by HLA-F OC-
expressing BCLs. KIR3DS1hiζ Jurkat reporter cells (red 
bars) were co-incubated for 2 h with acid-pulsed BCLs 
(reporter-to-target cell ratio = 1:10) in the presence of the 
indicated anti-KIR antibodies or KIR-Fc constructs and their 
respective isotype controls (each at 50 μg/mL) and reporter 
activity was measured. Labels: mIgG1, mouse IgG1 isotype 
control; anti-KIR3DS1, anti-KIR3DS1/L1 (clone: Z27) 
antibody; anti-KIR2DL3, anti-KIR2DL2/L3 (clone: DX27) 
antibody; hIgG1, human IgG1 isotype control; KIR3DS1-Fc, 
KIR3DS1-Fc fusion construct with Fc region of hIgG1; 
KIR2DL3-Fc, KIR2DL3-Fc fusion construct with Fc region of 
hIgG1. Data represents n = 3 technical replicates and is 
representative of n = 2 independent experiments. 
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2.4 MATERIALS AND METHODS 
Cell lines and antibodies 
721.221 and Jurkat (clone E6.1; ATCC) cell lines (including transductants) were 
grown in RPMI-1640 supplemented with 10% fetal bovine serum (Sigma-Aldrich), 2 mM 
L-glutamine (Gibco), 100 U/mL penicillin (Gibco), and 100 U/mL streptomycin (Gibco) at 
37°C/5% CO2. EBV-transformed B-cell lines (BCLs) were generated from peripheral 
blood mononuclear cells from donors bearing specific HLA genotypes; BCLs were also 
grown in the same media and conditions as 721.221 and Jurkat cells. The following 
purified antibodies were used for cell line-based staining and/or blocking assays: anti-
KIR3DS1/L1 (clone: Z27.3.7, Beckman Coulter), anti-KIR3DL1 (clone: DX9, 
BioLegend), anti-KIR3DL1/L2/S1+2DS2/S4/S5/L2 (clone: 5.133, Miltenyi), anti-
KIR2DL2/L3/S2 (clone: DX27, Miltenyi), anti-pan-HLA-I complex (i.e. anti-HLA-
A,B,C,E,F,G +β2m) (clone: W6/32, BioLegend), anti-HLA-B,C open conformers (clone: 
HC10; tebu-bio), and anti-HLA-A,G open conformers (clone: HCA2, tebu-bio), anti-CD3 
(clone: HIT3a, BioLegend), anti-CD4 (clone: RPA-T4, BioLegend), and anti-CD69 
(clone: FN50, BioLegend). 
 
KIR-Fc binding to HLA-I-coated beads 
Classical HLA-I-coated beads used were LABScreen single HLA-I beads (One 
Lambda). Acid pulsing of HLA-I-coated beads was performed by resuspending beads in 
50 μL of 300 mM glycine (pH 2.4), incubating at room temperature for exactly 2 min, 
and washing three times with 1 mL of HBSS. Untreated and acid-pulsed beads were 
stained according to the manufacturer’s instructions with KIR-Fc constructs (R&D 
 29 
Systems) diluted to the indicated concentrations in PBS. Binding to beads was 
measured on a Bio-Plex 3D Suspension Array system using Luminex xMAP technology 
(Bio-Rad). To generate non-classical HLA-I-coated beads, biotinylated monomers of 
HLA-E/β2m/VMAPRTLVL, HLA-F/β2m, and HLA-G/β2m/KGPPAALTL were purchased 
from Immune Monitoring Lab at Fred Hutchinson Cancer Research Center, Seattle, WA, 
and loaded onto streptavidin-coated beads (Life Technologies). Acid pulsing was 
performed as before. KIR-Fc staining was performed at the indicated concentrations for 
45 min at 4°C while shaking. Beads were then washed and stained with goat anti-
human IgG(Fc) F(ab’)2 PE-conjugated antibody (Life Technologies) diluted 1:50 for 30 
min at 4°C while shaking. Beads were subsequently washed and fixed with 4% 
paraformaldehyde in PBS (Affymetrix) before flow cytometric analysis. 
 
Lentiviral transduction/transfection 
Jurkat cells stably expressing genes of interest were generated via lentiviral 
transduction. Gene constructs were designed accordingly and ordered from GeneArt 
(Life Technologies). Constructs were cloned into a lentiviral transfer vector containing 
an SFFV promoter and IRES-driven puromycin resistance. This backbone vector was 
generated by cloning the SFFV promoter from pAPM59 into pLVX-EF1α-IRES-Puro 
(Clontech). HEK293T cells (ATCC) were transfected with a VSV-G envelope vector 
(pHEF-VSVG, obtained from NIH AIDS Reagent Program), HIV-1 gag-pol packaging 
vector (psPAX2, obtained from NIH AIDS Reagent Program), and the transfer vector of 
interest. Lentivirus-containing supernatants were harvested 3 d after transfection and 
used to transduce Jurkat cells, which were subsequently selected in 1 μg/mL puromycin 
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and sorted for gene expression by fluorescence-activated cell sorting (FACS). 721.221 
HLA transductants were previously generated by retroviral transduction (by Christian 
Brander, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA) or generated via 
lentiviral transduction for this study, with the exception of HLA-G-expressing 721.221 
cells, which were a kind gift from Jack Strominger (Department of Stem Cell and 
Regenerative Biology, Harvard University, Cambridge, MA). β2m-knockout (β2m-KO) 
Jurkat cells were generated KIRζ Jurkat reporter cell lines. For this, Jurkat cells were 
stably transduced with S. pyogenes Cas9 (lentiCas9-Blast was a gift from Feng 
Zhang60; Addgene plasmid # 52962) and selected in 5 μg/mL blasticidin S (Gibco). 
Jurkat-Cas9 cells were electroporated with a β2m-targeting gRNA CRISPR vector 
(kindly provided by Leonardo Ferreira, Department of Stem Cell and Regenerative 
Biology and Department of Molecular and Cellular Biology, Harvard University, 
Cambridge, MA, and Thorsten Meissner, Department of Stem Cell and Regenerative 
Biology, Harvard University, Cambridge, MA; published in 61) and sorted for loss of HLA 
expression. Jurkat-β2m-KO cells were subsequently transduced with KIRζ chimeric 
constructs. 
 
KIRζ Jurkat reporter cell assay 
KIRζ-Jurkat reporter cells were incubated with target cells at a reporter:target cell 
ratio of 1:10 at 37°C/5% CO2 for 2–2.5 h for acid-pulse experiments or for 8 h for 
experiments where acid pulsing was not a condition. For antibody blockade 
experiments, antibodies were pre-incubated with relevant cells (reporters or targets) for 
30 min at 4°C before co-incubation of reporter and target cells; the antibodies remained 
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during the co-incubation. After the co-incubation, cells were stained with anti-CD3 and 
anti-CD69 antibodies and CD69 expression of reporter cells relative to negative and 
positive controls was assessed and used as a measure of reporter activity.  
 
Surface Plasmon Resonance (SPR) 
SPR measurements were conducted in HBS-EP buffer using a Biacore 3000 
system (Biacore AB). To assess binding of various KIR-Fc constructs to HLA-F open 
conformers, biotinylated HLA-F monomers were immobilized onto a SA (streptavidin) 
sensor chip (GE Healthcare) to approximately 1000 response units (RU). A blank flow 
cell with no immobilized ligand was used as a reference flow cell. Injections of 60 μL of 
KIR-Fc constructs diluted in PBS to the indicated concentrations were performed at a 
flow rate of 20 μL/min, with a subsequent 10 min run of buffer to allow sufficient 
dissociation. Regeneration after each injection was done with two pulses of 100 μL of 
10 mM glycine∙HCl, pH 2.5, at a flow rate of 100 μL/min. Raw sensograms were 
corrected by double referencing (subtracting from the reference flow cell response and 
from PBS injection response). All experiments were done at standard temperature 
(25°C). 
 
Data Acquisition and Analysis 
Flow cytometry data were analyzed using FlowJo software version 7.6 (Tree 
Star) and statistical analyses were performed using GraphPad Prism 6 (GraphPad 
Software). KIR-Fc binding and CD69 reporter cell expression values are shown as 
mean values with error bars representing one standard deviation (SD). SPR data was 
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analyzed using BIAevaluation Software (GE Healthcare); given the dimeric nature of the 
KIR-Fc analyte, the bivalent analyte model was used to obtain proper fit of kinetic 
curves. 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 3: The physiological impact and regulation of 
KIR3DS1:HLA-F interactions 
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3.1 SUMMARY 
The activating NK-cell receptor KIR3DS1 has been implicated in the outcome of 
various human diseases, including delayed HIV-1 disease progression, yet a ligand that 
accounts for its biological effects remained unknown. A previous screen revealed that 
KIR3DS1 binds HLA-F OCs, which was validated biochemically and functionally (see 
Chapter 2). In this study, we found that primary human KIR3DS1+ NK cells 
degranulated and produced antiviral cytokines IFN-γ, MIP-1β, and TNF-α upon 
encountering HLA-F OCs. KIR3DS1+ NK cells also exhibited a superior activity at 
suppressing HIV-1 replication in vitro, as has been previously reported. Exploring the 
cellular context of HLA-F expression, we found that CD4+ T-cell activation triggered 
HLA-F transcription and expression and induced binding of soluble KIR3DS1-Fc. HIV-1 
infection of activated CD4+ T cells further increased HLA-F transcription, but partially 
decreased KIR3DS1 ligand expression, indicating an immune-evasion mechanism. In 
monocytic and T-cell lines transduced with FLAG-tagged HLA-F, we find that HLA-F is 
expressed intracellularly. However, mobilization of HLA-F to the cell surface could be 
achieved with cellular activation, IFN-γ treatment, and most potently by low-temperature 
incubation. Altogether, we established that KIR3DS1:HLA-F interactions are functionally 
relevant in primary human NK cells and demonstrate tight and complex regulation of 
HLA-F expression that may explain the widespread influence of KIR3DS1 in human 
diseases. 
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3.2 RESULTS 
3.2.1 HLA-F OCs potently trigger a polyfunctional response in primary 
KIR3DS1+ NK cells 
 To assess the functional impact of HLA-F OC binding to KIR3DS1 in primary 
human NK cells, KIR3DS1+ and KIR3DS1– NK-cell clones (NKCLs) were generated via 
limiting dilution cloning from peripheral blood NK cells from a healthy KIR3DS1-
homozygous donor. NKCLs were confirmed to be CD56+KIR3DL1–LILRB1– to ensure 
proper functionality, and had variable expression of KIR2Ds (Supplementary Fig. 
S3.1). These NKCLs were seeded into individual well plates coated with human IgG (for 
CD16 crosslinking), anti-KIR3DS1/L1 antibody (for KIR3DS1 crosslinking), or 
monomers of HLA-E, -F, or -G. To assess NKCL responses to plate-bound ligands, we 
measured cytotoxic granule exocytosis (i.e. degranulation), as determined by surface 
expression of CD107a, and production of antiviral cytokines IFN-γ, TNF-α, and MIP-1β 
by intracellular staining. Plate-bound HLA-F strongly and significantly triggered 
degranulation in KIR3DS1+ NKCLs (Fig. 3.1) but not KIR3DS1– NKCLs (Fig. 3.2). The 
magnitude of this response was comparable to crosslinking of KIR3DS1 and CD16, and 
was able to be significantly reduced by addition of soluble anti-KIR3DS1/L1 antibody 
(Fig. 3.2). Plate-bound HLA-E and HLA-G produced a weak response in some but not 
all NKCLs, and this activation could not be blocked with soluble anti-KIR3DS1/L1 
antibody. The observed effects were not due to intrinsic differences in response 
capacity, as all NKCLs (except for one that was CD16–) were similarly triggered by 
CD16 crosslinking. In addition, HLA-F elicited production of antiviral cytokines IFN-γ, 
TNF-α, and MIP-1β in KIR3DS1+ (but not KIR3DS1–) NKCLs, and these responses 
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could be blocked with soluble anti-KIR3DS1/L1 antibody (Fig. 3.1 and Fig. 3.2).  
Interestingly, KIR3DS1+ NKCLs had an intrinsic superior capacity to produce antiviral 
cytokines when compared to KIR3DS1– NKCLs when encountering the same stimuli 
(Supplementary Fig. S3.2). Altogether, these data demonstrate that HLA-F triggers a 
potent activating signal via KIR3DS1 that results in polyfunctional responses by primary 
NK cells. 
 
Figure 3.1: HLA-F OCs trigger a polyfunctonal response in KIR3DS1+ NK-cell clones. Flow plots of a 
KIR3DS1+ NKCL that was seeded onto well plates coated with irrelevant protein (negative control), anti-
KIR3DS1/L1 antibody (plate-bound anti-KIR3DS1), or HLA-F monomers (plate-bound HLA-F), and 
incubated for 5 h in the presence of a fluorophore-conjugated anti-CD107a antibody and brefeldin A, 
followed by surface stain for NK-cell markers and intracellular cytokine stain for IFN-γ, TNF-α, and MIP-1β 
(for details, see Materials and Methods). 
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Figure 3.2: HLA-F OCs trigger degranulation and antiviral cytokine production in primary NK cells 
via KIR3DS1. KIR3DS1+ (red dots and lines) and KIR3DS1– NKCLs (black dots and lines) were seeded 
onto well plates coated with irrelevant protein (fetal bovine serum; neg. ctrl.), human IgG (hIgG), anti-
KIR3DS1/L1 antibody (clone: Z27; anti-KIR3DS1), or monomers of HLA-E, -F, or -G. For each plate-
bound ligand condition, antibody-mediated blockade was performed by incubating NKCLs in the presence 
of mouse IgG1 isotype control antibody (+iso) or soluble anti-KIR3DS1/L1 antibody (+α-3DS1) (25 μg/mL 
each). NKCLs were incubated for 5 h with anti-CD107a fluorescent antibody and brefeldin A, followed by 
surface stain for NK-cell markers and intracellular cytokine stain for IFN-γ, TNF-α, and MIP-1β (for details, 
see Materials and Methods). The raw percentages of CD107a+ NKCLs exposed to the indicated plate-
bound ligands are presented in the upper six panels, and the raw percentages of IFN-γ+, TNF-α+, and 
MIP-1β+ NKCLs exposed to plate-bound HLA-F are presented in the bottom three panels. One CD16– 
NKCL is indicated in hIgG. For each plate-bound ligand and marker, one-way ANOVA with Bonferroni 
multiple comparisons test comparing select columns was performed, and all statistically significant 
differences are presented (*, **, ***, and **** denote, p < 0.05, < 0.01, < 0.001, and < 0.0001, 
respectively). 
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3.2.2 Activation of primary CD4+ T cells induces KIR3DS1 ligand expression at 
the cell surface 
A previous study demonstrated that HLA-F can be expressed on the surface of 
activated lymphocytes62. To study KIR3DS1 ligand expression in a biologically relevant 
context, HLA-F expression and KIR3DS1-Fc binding to primary resting CD4+ T cells and 
CD4+ T cells stimulated with anti-CD3/28 beads and IL-2 was assessed. A Western 
blot-suitable anti-HLA-F antibody (validated in Supplementary Fig. S3.3) was used to 
assess protein levels, and resistance to endoglycosidase H (Endo H) digestion served 
as a measure of cell-surface expression. Endo H is a glycosidase that removes 
immature N-glycans from glycoproteins that have not undergone Golgi processing; thus, 
glycoproteins shuttled to the cell surface through the Golgi are rendered Endo H-
resistant (i.e. there is no band shift on protein gel electrophoresis). Results showed that 
whereas unstimulated CD4+ T cells do not have any detectable levels of HLA-F protein, 
stimulated CD4+ T cells express HLA-F protein in a predominantly Endo H-resistant 
form, consistent with cell-surface expression (Fig. 3.3a); similar results were obtained 
with different stimulation conditions (48 h treatment with 12.5 ng/mL phorbol 12-
myristate 13-acetate and 0.335 μM ionomycin; data not shown).  
To determine if the up-regulation of HLA-F protein in activated CD4+ T cells was 
transcriptionally induced, HLA-F mRNA levels were assessed via flow cytometry-based 
fluorescent in situ hybridization (FISH) (detailed in Materials and Methods). HLA-F 
mRNA-specific probes were used after testing their sensitivity and specificity in HLA-F+ 
and HLA-F– cell lines (Supplementary Fig. S3.4). Activation of CD4+ T cells increased 
the    levels    of    HLA-F   mRNA   transcripts   (Fig. 3.3b),   indicating   that   HLA-F   is 
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Figure 3.3: Activated CD4+ T cells express HLA-F on the cell surface and bind KIR3DS1-Fc. (a) 
Purified CD4+ T cells were unstimulated or stimulated with high-dose IL-2 (100 U/mL) and anti-CD3/28 
beads for 14 days. Cell lysates underwent Endo H, PNGase F, or mock digestion, and 
reducing/denaturing SDS-PAGE was performed, followed by immunoblotting for HLA-F and β-actin 
(loading control). (b) CD4+ T cells from a healthy donor were rested in culture medium or activated with 
PMA+ionomycin for 24 h before performing fluorescent in situ hybridization and flow cytometry to assess 
HLA-F mRNA levels; this data is representative of four independent donors. (c, d) Purified CD4+ T cells 
from four donors were activated with anti-CD3/28 beads and IL-2 (100 U/mL) for 6 d or left untreated and 
grown in modified media for 48 h prior to staining with KIR3DS1-Fc (25 μg/mL). The percentage of cells 
binding KIR3DS1-Fc was determined by setting gate based on sample stained only with secondary 
antibody (2ry only, i.e., no KIR-Fc) and these were plotted in d; histograms from a representative donor 
are depicted in c. Four donors were chosen based on HLA-B types, which were the following: 
B*08:01/B*18:01, B*08:01/B*14:02, B*44:02/B*44:02, and B*27:05/B*57:01. Paired t test was performed 
for unstimulated versus stimulated CD4+ T cells (**** denotes p < 0.0001). 
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transcriptionally induced in CD4+ T cells upon activation. Furthermore, KIR3DS1-Fc 
bound significantly to stimulated CD4+ T cells, but not to unstimulated CD4+ T cells (Fig. 
3.3c and Fig. 3.3d, p < 0.0001). These results were consistent across donors with and 
without HLA-Bw4 allotypes, demonstrating that KIR3DS1 ligands are expressed on 
activated CD4+ T cells regardless of their HLA-I genotype, and strongly suggesting 
KIR3DS1 binding to HLA-F expressed on activated CD4+ T cells. 
 
3.2.3 HIV-1 infection of activated CD4+ T cells increases HLA-F transcription 
but partially decreases KIR3DS1 ligand expression, and is suppressed by 
KIR3DS1+ NK cells 
To assess the influence of HIV-1 infection on expression of KIR3DS1 ligands in 
CD4+ T cells, HLA-F mRNA levels and KIR3DS1-Fc binding were assessed using 
activated CD4+ T cells that were uninfected or infected with HIV-1 NL4-3. HLA-F mRNA 
levels were up-regulated in HIV-1–infected activated CD4+ T cells when compared to 
uninfected activated CD4+ T cells (Fig. 3.4c), indicating that HIV-1 infection further 
stimulated HLA-F mRNA transcription. In contrast, KIR3DS1-Fc binding was 
significantly decreased upon HIV-1 infection (Fig. 3.4a and Fig. 3.4b). The decrease in 
KIR3DS1-Fc binding was already observed in ‘early’ infected cells (defined as 
p24dimCD4+HLA-I+tetherin+), but was more pronounced in ‘late’ infected cells (defined as 
p24hiCD4dimHLA-Idimtetherindim), indicating an as-yet-unknown mechanism by which HIV-
1 might reduce KIR3DS1 ligand expression. This may be due to direct downregulation 
of HLA-F protein by HIV-1; however, due to the absence of an available flow cytometry-
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suitable antibody against HLA-F, it was not possible to directly quantify HLA-F surface 
expression levels on HIV-1–infected cells.  
 
Figure 3.4: Effect of HIV-1 infection on HLA-F expression and KIR3DS1-Fc binding. (a) CD4+ T cells 
from healthy donors were stimulated with IL-2 (100 U/mL) and anti-CD3/28 beads for 3 d, and were then 
cultured or infected with HIV-1 NL4-3. At 3 d post-infection (infection rate ~50%), fluorescent in situ 
hybridization and flow cytometry was performed to assess HLA-F mRNA levels. This data is 
representative of two independent experiments on two different donors. (b, c) Purified CD4+ T cells from 
five healthy donors were cultured in IL-2 (100 U/mL) and were either unstimulated or stimulated by plate-
bound anti-CD3/28 stimulation for 7 d. Stimulated cells were then either continually cultured or infected 
with HIV-1 NL4-3. At 3 d post-infection (infection rate among five donors was ~100%), cells were stained 
for KIR3DS1-Fc (25 μg/mL) as well as intracellular HIV-1 p24 and additional markers to assess HIV-1 
infection stage. Flow histogram in b depicts KIR3DS1-Fc binding to IL-2-cultured CD4+ T cells, stimulated 
CD4+ T cells, and stimulated CD4+ T cells that are ‘early’ HIV-1–infected (p24dimCD4+HLA-I+tetherin+) or 
‘late’ HIV-1–infected (p24hiCD4dimHLA-Idimtetherindim). In c, aggregate data for five healthy donors with 
background-subtracted median fluorescence intensities (bsMdFI) are shown with black lines connecting 
data points from each individual donor. 
 
To evaluate the antiviral capacity of KIR3DS1+ NK cells, HIV-1–infected 
autologous CD4+ T cells were co-cultured for seven days with KIR3DS1+ and KIR3DS1– 
NK-cell clones derived from a KIR3DS1 homozygous donor (for NK-cell receptor 
phenotypes, see Supplementary Fig. S3.5). Intracellular staining for HIV-1 p24 was 
performed to quantify the percentage of infected cells. Only KIR3DS1+ NK-cell clones 
were effective at suppressing HIV-1 replication in autologous CD4+ T cells, as seen by 
significantly less HIV-1 p24+ CD4+ T cells in the presence of KIR3DS1+ NK cells (5.48 % 
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± 1.60 %), relative to KIR3DS1– NK-cell clones (16.9 % ± 2.32 %; p < 0.01) or no NK 
cells added (mean 16.0 % ± 2.62 %, p < 0.01) (Fig. 3.5a and Fig. 3.5b). Thus, 
KIR3DS1+ NK cells have superior antiviral capacity towards HIV-1–infected autologous 
CD4+ T cells, as previously shown13, and HIV-1–mediated downregulation of KIR3DS1 
ligands on infected cells is not sufficient to enable complete immune evasion. 
 
Figure 3.5: KIR3DS1+ NK cells efficiently suppress HIV-1 replication in autologous CD4+ T cell in 
vitro. (a, b) KIR3DS1+ and KIR3DS1– NKCLs were co-incubated with autologous HIV-1–infected CD4+ T 
cells for 7 d, after which intracellular staining for HIV-1 p24 and flow cytometry was performed to quantify 
amount of remaining HIV-1–infected CD4+ T cells. Aggregate results are presented a and representative 
flow cytometry plots are presented in b. For a, one-way ANOVA was performed with Tukey multiple 
comparisons test comparing all columns (** denotes p < 0.01). 
 
3.2.4 HLA-F is expressed intracellularly when transduced into T-cell, 
monocytic, and myeloid cell lines. 
 To explore how HLA-F expression is regulated, various cell lines (i.e. Jurkat, 
THP-1, and K562 cells) were transduced with N-terminally FLAG-tagged HLA-F (HLA-
FFLAG) to allow detection by anti-FLAG antibody staining. Consistent with previous 
studies56, all cell lines did not express HLA-FFLAG on the cell surface, but rather 
expressed it intracellularly (Fig. 3.6 and Fig. 3.7). To assess whether cellular activation 
or inflammatory cytokine treatment would mobilize HLA-F to the cell surface, as has 
been previously document in human immune and non-immune cells62,63, THP-1 cells  
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Figure 3.6: HLA-F is expressed intracellularly. Jurkat and K562 cells transduced with HLA-FFLAG were 
stained with APC-conjugated anti-FLAG antibody to assess surface expression of HLA-FFLAG, and then 
subsequently fix, permeabilized, and stained intracellularly with PE-conjugated anti-FLAG antibody to 
assess intracellular expression. Note: HLA-FFLAG transduction efficiency differed by cell line. 
 
were treated with PMA, IFN-γ, or both. PMA is a DAG analogue that activates protein 
kinase C and other cellular factors to induce potent cellular activation, and IFN-γ is a 
pro-inflammatory cytokine that upregulates MHC class I and II expression among many 
pleiotropic functions. Indeed, both PMA and IFN-γ induced cell-surface expression of 
HLA-FFLAG in THP-1 cells, with IFN-γ being more potent than PMA, and both exhibiting 
synergy when combined (Fig. 3.7). Of note, IFN-γ treatment also induced expression of 
endogenous HLA-DR and HLA-G (data not shown), as has been previously reported for  
 
Figure 3.7: Cell-surface expression of HLA-F is induced by PMA and IFN-γ. THP-1 cells transduced 
with HLA-FFLAG were either untreated or treated with 50 ng/mL PMA, 100 U/mL IFN-γ, or both for 48 h. 
Cells were subsequently stained with anti-FLAG antibody to assess cell-surface expression of HLA-F. 
Untransduced THP-1 cells were used as a negative control for staining. 
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THP-1 cells64. Of interest, we serendipitously discovered that incubation of THP-1-HLA-
FFLAG cells at a low temperature (26°C) potently mobilizes HLA-FFLAG to the cell surface, 
resulting in very high surface expression (Fig. 3.8); this also occurred in Jurkat cells, 
although to a lesser extent (Supplementary Fig. S3.6). This finding, however, is not 
unprecedented given that lower temperatures increase the stability of HLA-I OCs and 
result in increased cell surface expression65; whether this increased stability is leading 
to increasing trafficking to the cell surface or decreasing endocytosis in the case of 
HLA-F remains to be determined. Altogether, our data shown that HLA-F is a 
predominantly intracellular HLA-I gene whose surface expression is tightly regulated 
and induced upon cellular activation or exposure to pro-inflammatory cytokines. 
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Figure 3.8: Low-temperature incubation potently mobilizes HLA-F 
to the cell surface. THP-1-HLA-FFLAG cells were cultured under normal 
conditions (37°C and 5% CO2) or incubated at 26°C (and 5% CO2) for 
18 h. Cells were subsequently stained with anti-FLAG antibody to 
assess cell-surface expression of HLA-F. Untransduced THP-1 cells 
were used as a negative control for staining. 
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3.3 MATERIALS AND METHODS 
Cell lines 
Jurkat (clone E6.1; ATCC), K562, and THP-1 cell lines (including transductants) 
were grown in RPMI-1640 supplemented with 10% fetal bovine serum (Sigma-Aldrich), 
2 mM L-glutamine (Gibco), 100 U/mL penicillin (Gibco), and 100 U/mL streptomycin 
(Gibco) at 37°C/5% CO2. The following purified antibodies were used for blocking or 
plate-bound ligand assays: anti-KIR3DS1/L1 (clone: Z27.3.7, Beckman Coulter), 
human. 
 
Lentiviral transduction/transfection 
Cell lines stably expressing genes of interest were generated via lentiviral 
transduction. Gene constructs were designed accordingly and ordered from GeneArt 
(Life Technologies). HLA-F sequence was obtained from NCBI (accession: P30511), 
and FLAG sequence was added after the signal peptide sequence. Constructs were 
cloned into a lentiviral transfer vector containing an SFFV promoter and IRES-driven 
puromycin resistance. This backbone vector was generated by cloning the SFFV 
promoter from pAPM59 into pLVX-EF1α-IRES-Puro (Clontech). HEK293T cells (ATCC) 
were transfected with a VSV-G envelope vector (pHEF-VSVG, obtained from NIH AIDS 
Reagent Program), HIV-1 gag-pol packaging vector (psPAX2, obtained from NIH AIDS 
Reagent Program), and the transfer vector of interest. Lentivirus-containing 
supernatants were harvested 3 d after transfection and used to transduce cell lines, 
which were subsequently selected in 1 μg/mL puromycin and in some cases sorted for 
gene expression by fluorescence-activated cell sorting (FACS). 
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Primary human CD4+ T-cell isolation, stimulation, infection, and staining with KIR-Fc 
and HLA-F mRNA probes 
CD4+ T cells were isolated from donor PBMCs by indirect magnetic labeling and 
negative selection, using the CD4+ T cell isolation kit II (Miltenyi) according to the 
manufacturer’s protocol. Stimulations were done differently depending on the 
experiment. Stimulations for Western Blots were done with anti-CD3/28 Dynabeads 
(Life Technologies) were done at a bead:cell ratio of 2:1 and culturing in supplemented 
RPMI with IL-2 (100 U/mL) for the indicated amounts of time. Stimulations for flow 
cytometry-based fluorescent in situ hybdridization were done with phorbol 12-myristate 
13-acetate (12.5 ng/mL) and ionocymin (0.335 μM) (Cell Stimulation Cocktail used at 
0.25X; eBioscience) for the indicated amounts of time. Stimulations for KIR-Fc staining 
and HIV-1 infection were done for the indicated amounts of time in supplemented RPMI 
with IL-2 (100 U/mL) on non-tissue culture-treated flat-bottom 48-well plates previously 
pre-coated with anti-CD3 (clone: OKT3, BioLegend) and anti-CD28 (clone: CD28.2, 
BioLegend) antibodies each at 10 μg/mL. HIV-1 infection was done by resuspending ~1 
× 106 activated CD4+ T cells in 1 mL of supplemented RPMI containing 100 U/mL of IL-
2 and adding 1 × 105 TCID50 of replication-competent HIV-1 NL4-3. Cell were 
immediately spinfected (centrifuging for 2 h at 1,500 × g at 37°C) and incubated at 
37°C/5% CO2 for 72 to allow for viral replication. For KIR-Fc staining of cells, cells were 
first stained with LIVE/DEAD® Fixable Blue Dead Cell Staining Kit (Life Technologies) 
following manufacturer’s instructions, and then stained with 25 μg/mL of KIR3DS1-Fc 
for 45 min at 4°C while shaking, after which the cells were washed and stained with 
anti-CD3 (clone: UCHT1, BioLegend), anti-CD4 (clone: RPA-T4, BioLegend), anti-pan-
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HLA-I complex (clone: W6/32, BioLegend), anti-tetherin (clone: RS38E), and goat anti-
human IgG(Fc) F(ab’)2 PE-conjugated antibody (Life Technologies) for 30 min at 4°C 
while shaking. Cells were subsequently washed and subjected to fixation and 
permeabilization with the FIX & PERM ® Cell Fixation and Cell Permeabilization Kit 
(Life Technologies) to stain with anti-HIV-1 p24 (clone: KC57, BD Biosciences). Cells 
were subsequently washed and resuspended in PBS, except in assays where fixation 
and permeabilizationn was not done, in which case cells were fixed with 4% 
paraformaldehyde in PBS (Affymetrix) before flow cytometric analysis. Fluorescent in 
situ hybdridization was done with the PrimeFlow™ RNA Assay from Affymetrix with 
custom designed HLA-F mRNA specific probes following manufacturer’s intructions. 
Flow cytometric analyses of samples were performed on a BD LSRFortessa. 
 
Western Blot 
2 × 106 Cells were lysed in 100 μL of lysis buffer (20 mM Tris∙HCl, 100 mM NaCl, 
1 mM EDTA, 0.5% Triton X-100, pH 8.0, all reagents from Sigma-Aldrich) containing 1X 
Halt™ protease and phosphatase inhibitor cocktail (Life Technologies). Nuclei were 
pelleted supernatants containing cytoplasmic and plasma membrane proteins were 
collected. Lysates were treated with Endo Hf (New England Biolabs), PNGase F (New 
England Biolabs), or mock treated according to manufacturer’s instructions. Reaction 
products were denatured and reduced, and run on NuPAGE Novex 4-12% Bis-Tris 
protein gels (Life Technologies). Gel products were transferred over to a PVDF 
membrane, and dual immunoblotting was done with mouse anti-β-actin (clone: mAbcam 
8224, Abcam) and rabbit anti-HLA-F (clone: EPR6803, Abcam) primary antibodies and 
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IRDye 800CW goat anti-human IgG(H+L) (LI-COR) and IRDye 680RD goat anti-rabbit 
IgG(H+L) (LI-COR) secondary antibodies. The blots were visualized using an Odyssey 
imaging system (LI-COR) and images were analyzed using Image Studio 3.1 software 
(LI-COR). 
 
Generation of primary NK-cell clones 
Primary human NK cells isolated from peripheral blood mononuclear cells 
(PBMCs) of healthy human donors were subcloned by limiting dilution in two manners. 
For the HIV-1 replication inhibition assay, NK cells were subcloned in the presence of 
feeders and maintained in NK-cell cloning medium consisting of supplement RPMI 
additionally supplemented with 5% human serum (Sigma-Aldrich), 1X MEM-NEAA 
(Gibco), 1X sodium pyruvate (Gibco), 100 μg/mL kanamycin, 450 U/mL IL-2 (AIDS 
Reagent Program, NIH) using a protocol adapted from a previously reported method66. 
Briefly, NK cells were isolated from peripheral blood mononuclear cells (PBMCs) from a 
KIR3DS1+/+(homozygous) donor via magnetic negative selection (NK-cell isolation kit 
from Miltenyi), added to a mix of irradiated feeders consisting of freshly isolated 
allogeneic (PBMCs) combined with log-phase-growth RPMI 8866 cells (Sigma-Aldrich) 
at a 10:1 ratio in cloning medium containing 1 μg/mL phytohaemagglutinin (PHA; 
Fisher) and mixed thoroughly before plating at 100 µL/well (1 NK cell/well) in 96-well 
plates and incubated for 14 days at 37°C/5% CO2. After 14 days, wells that had 
outgrowth of cells were transferred to 48-well plates and maintained in NK-cell medium 
with frequent media exchange (approximately every 3 days). For plate-bound ligand 
assays, NK cells were subcloned in the presence of irradiated K562 cells expressing 
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mbIL-15 and CD137L (kind gift from Dario Campana, published in 67) and modified NK-
cell cloning media consisting of RPMI supplemented with 15% fetal bovine serum 
(Sigma-Aldrich), 5% human serum (Sigma-Aldrich), 2 mM L-glutamine (Gibco), 1X 
MEM-NEAA (Gibco), 1X sodium pyruvate (Gibco), 100 μg/mL Primocin™ (Invivogen), 
500 U/mL IL-2 (AIDS Reagent Program, NIH), with the addition of the following four 
cytokines to supplant the need for PBMC feeders: 5 ng/mL IL-15 (Peprotech), 10 ng/mL 
IL-12 (Peprotech), 40 ng/mL IL-18 (Peprotech), and 20 ng/mL IL-21 (Peprotech). NK-
cell clones that grew out were continually cultured in modified NK-cell cloning media 
without additional cytokines. Cells were phenotyped by flow cytometry with the following 
antibodies: anti-CD56-BV421 (BioLegend), anti-CD16-BV785 (BioLegend), anti-
NKG2A-APC (Beckman Coulter), anti-LILRB1-PE-Cy5 (BD Biosciences), anti-
KIR3DL1/S1-PE (Beckman Coulter), anti-KIR2D1/S1-PerCP-Cy5.5 (clone: HP-MA4, 
BioLegend), and anti-KIR2DL2/L3 (clone: DX27, BioLegend). Only NK-cell clones that 
were CD3–CD56+ (rarely CD16–) and LILRB1– were used for subsequent assays to 
ensure proper functionality. 
 
NK-cell degranulation and intracellular cytokine staining assay 
Non-tissue culture-treated flat-bottom 96-well plates were coated overnight at 
4 C with 50 μL the following ligands diluted in PBS: 1 mg/mL human γ-globulins 
(Thermo Scientific), 1 μg/mL of both anti-CD335 (a.k.a. NKp46) (clone: 9E2, BioLegend) 
and anti-CD2 (clone: TS1/8, BioLegend) antibody, 1 μg/mL of anti-KIR3DS1/L1 (clone: 
Z27.3.7, Beckman Coulter), 10 μg/mL of HLA-E, -F, or -G monomer, or 0.5% bovine 
serum albumin (Miltenyi). ~1 × 104 NK cells in 100 µL of supplemented RPMI containing 
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3 µL of anti-CD107a-PE-Cy7 antibody (BioLegend) and 5 μg/mL brefeldin A (Biolegend) 
and in the presence of anti-KIR3DS1/L1 antibody or isotype control antibody (mouse 
IgG1, clone: MG1-45, BioLegend) were seeded onto ligand-coated plate wells. After a 
5-h incubation at 37°C/5% CO2, cells were first stained with LIVE/DEAD® Fixable Blue 
Dead Cell Staining Kit (Life Technologies) following manufacturer’s instructions, and 
then stained with anti-CD56-BV421 (clone: HCD56, BioLegend) and anti-CD16-BV785 
(clone: 3G8, BioLegend) antibodies for 15 min at 4°C. Cells were then fixed with BD 
Cytofix/Cytoperm solution (BD Biosciences) and permeabilized with BD Perm/Wash 
solution (BD Biosciences) following manufacturer’s instructions, after which intracellular 
cytokine staining was carried out using the following antibodies: anti-IFN-γ-Alexa Fluor 
647 (clone: 4S.B3, BioLegend), anti-TNF-α-BV650 (clone: Mab11, BioLegend), and 
anti-MIP-1β-PerCP-eFluor710 (clone: FL34Z3L, eBioscience). After washing, flow 
cytometric analysis was performed on a BD LSR Fortessa. 
 
NK-cell co-incubation with HIV-1–infected autologous CD4+ T cells 
PBMCs from the same donor from which NK-cell clones were generated were 
thawed and CD4+ T cells were enriched via magnetic negative selection with the 
EasySep™ Human CD4+ T Cell Enrichment Kit (StemCell). CD4+ T cells were cultured 
overnight in supplemented RPMI containing 50 U/mL of IL-2 and 1 μg/mL PHA. The 
next day, cells were washed and resuspended at 1 × 106 cells/mL in supplemented 
RPMI containing 50 U/mL of IL-2. HIV-1 JR-CSF was added to a final concentration of 1 
× 104 TCID50/mL, and cells were incubated for 4 h at 37°C/5% CO2. Afterwards, infected 
CD4+ T cells were washed, resuspended in NK cell medium, and plated in a round-
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bottom 96-well plate at 5 × 104 cells/well. NK-cell clones from the same donor were 
added to individuals wells at 1.25 × 105 cells/well (NK cell:CD4+ T cell ratio = 2.5:1). 
Cells were co-cultured for 7 days, after which surface staining for CD3 and CD4 and 
intracellular staining for HIV-1 p24 was performed for flow cytometry assessment.  
 
Human Samples and Viruses 
Frozen peripheral blood mononuclear cells (PBMCs) from healthy donors were 
used in this study in accordance to protocols approved by Partners Human Research 
Committee and Institutional Review Board of Massachusetts General Hospital. HLA/KIR 
genotypes of selected human samples were determined prior to this study by high-
resolution HLA typing performed at the HLA-typing laboratory of the National Cancer 
Institute, National Institutes of Health, and Sanger Sequencing-based KIR genotyping 
performed by Mary Carrington’s laboratory. HIV-1 NL4-3 and HIV-1 JR-CSF were 
purchased from the Virology Core of the Ragon Institute of MGH, MIT, and Harvard, 
and are quality controlled for infectivity and titered on stimulated human PBMCs by 
standard endpoint TCID50 assay. 
 
HLA-FFLAG–transduced cell lines assays 
 For FLAG staining, PE- and APC-conjugated anti-FLAG antibodies (clone: L5, 
BioLegend) were used. In experiments that assessed cell-surface versus intracellular 
HLA-FFLAG expression, cells were stained with APC-conjugated anti-FLAG antibody, and 
then fixed with BD Cytofix/Cytoperm solution (BD Biosciences) and permeabilized with 
BD Perm/Wash solution (BD Biosciences) following manufacturer’s instructions, after 
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which intracellular staining with PE-conjugated anti-FLAG antibody was performed. 
Flow cytometric analysis followed.  
   
Data Acquisition and Analysis 
Flow cytometry data was acquired on BD LSR Fortessa and analyzed using 
FlowJo software version 7.6 (Tree Star) and statistical analyses were performed using 
GraphPad Prism 6 (GraphPad Software). 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 4: Heparan sulfate proteoglycans are ligands of KIR3DS1 
and other NK-cell receptors 
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4.1 SUMMARY 
 While an overwhelming majority of NK-cell receptor:ligand interactions studied 
are protein:protein in nature, the role of protein:carbohydrate interactions in NK-cell 
function exists and could be more fully explored. In this study, we performed a genome-
wide CRISPR/Cas9 knock-out screen for KIR3DS1 ligands and identified heparan 
sulfate (HS) as a KIR3DS1 ligand. This was validated biochemically by surface plasmon 
resonance and on cell lines, and was shown to be completely dependent on the 
presence of HS sulfate moieties. Further studies revealed that KIR3DL1, a highly 
homologous inhibitory allotype of KIR3DS1, also bound HS. As binding of other NK-cell 
receptors to HS has been described (for NKp30, NKp44, NKp46, and KIR2DL4), these 
data indicate that NK-cell receptor:HS interactions are widespread and could play 
important roles in NK-cell–receptor regulation and target-cell recognition that need to be 
further investigated. 
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4.2 BACKGROUND 
Unlike T cells, which rely primarily on the T-cell receptor to recognize specific 
MHC complexes presenting peptides sampled from intracellular and/or extracellular 
compartments, NK-cell function is dictated by germline-encoded activating and 
inhibitory receptors that interact with a plethora of ligands expressed on target cells. Of 
all the receptor:ligand interactions studied, an overwhelming number are protein:protein 
in nature, leaving a major gap in our knowledge of the role of non-protein NK-cell–
receptor ligands. 
A major group of non-protein NK-cell–receptor ligands are carbohydrates 
expressed on target cells. Indeed, all cells in the body bear a glycocalyx, a term used to 
refer to the entire array of glycans coating the cell surface68. However, this term is highly 
misleading because it grossly underestimates the complexity and heterogeneity of these 
glycans. Cell surface glycans can be (i) non-covalently adsorbed to the cell surface, (ii) 
covalently linked to lipids, called glycolipids, or (iii) covalently linked to proteins in the 
form of glycoproteins or proteoglycans. Proteoglycans (PGs), in particular, consist of a 
core protein with one or more covalently linked glycosaminoglycans (GAGs), which 
usually dictate most or all of the PG’s function. GAGs are long, unbranched 
polysaccharides whose disaccharide building blocks consist of an amino sugar and a 
uronic acid or galactose and can be modified extensively by acetyl and sulfate 
substitutions. These modifications are exquisitely intricate and diverse, and tightly 
regulated on individual cells. 
There are five types of GAGs: hyaluronic acid (HA), keratan sulfate (KS), 
dermatan sulfate (DS), chondroitin sulfate (CS), and heparan sulfate (HS). The most 
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abundant GAGs found on most cell surfaces are HA and HS69. HA is a unique and 
relatively simple GAG that is unmodified (i.e. non-sulfated and non-acetylated) and does 
not exist as a PG. HS, on the other hand, is a GAG made as a PG by every cell in the 
body and plays a multitude of biological roles (reviewed in 70) including: barrier 
function71; coagulation72; wound repair73,74; development75,76; endocytosis77 and 
transcellular transport78; virus attachment and entry79–84; tumorigenesis85; cell adhesion 
and migration, including leukocyte homing86; signaling of growth factors87,88, 
morphogens, cytokines89, and chemokines90; and host defense91. HS biosynthesis 
begins in the endoplasmic reticulum (ER) with serial addition of specific glycosyl groups 
to generate a β-linked tetrasaccharide primer—Xyl(β1-4)Gal(β1-3)Gal(β1-3)Glc—on a 
serine residue of an HSPG protein core, a reaction catalyzed in series by XYLT1 and/or 
XYLT2, B4GALT7, B4GALT6, and B3GAT3. The possible HSPG protein cores are 
syndecans (1 through 4), glypicans (1 through 6), betaglycan, serglycin, and 
occasionally, neuropilin-1 and certain isoforms of CD44; all of these contain at least one 
Ser-Gly motif near a patch of acidic residues onto which HS is polymerized. Subsequent 
reactions by exostosin glycosyltransferases (EXT1 and EXT2) and exostosin-like 
glycosyltransferases (EXTL1, EXTL2, and EXTL3) add repeating β1-4-linked 
disaccharides of N-acetyl glucosamine and glucuronic acid. The extended 
polysaccharide can be subsequently modified in the Golgi by epimerization of 
glucuronic acid to iduronic acid catalyzed by GLCE, and by a complex array of 
sulfotransferase reactions. These sulfotransferase reactions are (i) N-deacetylation/N-
sulfation of GlcNAc by any of four enzymes (NDST1–4); (ii) 6-O-sulfation by any of 
three enzymes (HS6ST1–3); (iii) 2-O-sulfation by a single enzyme (HS2ST1); and (iv) 
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more infrequently92, 3-O-sulfation by any of several enzymes (HS3ST1–6). Fully formed 
HSPGs can be secreted or displayed on the cell surface, where they may be edited by 
sulfatases (SULF1 and SULF2). While the most well-known form of HS is heparin, a 
highly sulfated form that is made and secreted only by connective-tissue mast cells and 
used as an anti-coagulant, by far the most prevalent form is HSPGs found on cell 
surfaces. Much like DNA or RNA, HS does not have a single structure or sequence, but 
rather, the basic polysaccharide components that make HS vary depending on the cell 
type and cellular context under which they are made. Thus, HS has been referred to as 
“the most information-dense biopolymers found in nature”93. 
 Among its biological functions, HS has been shown to interact with numerous 
immune receptors. The natural cytotoxicity receptors (NCRs) NKp30, NKp44, and 
NKp46, which are widely expressed activating NK-cell receptors94, have been shown to 
bind to specific HS motifs. NKp30 and NKp46 bind to epitopes containing of 2-O-
sulfated iduronic acid and 6-O- and N-sulfated glucosamine, whereas NKp44 binds to 
epitopes containing 2-O-sulfated iduronic acid and N-acetylated glucosamine95. In 
addition, a genome-wide siRNA screen discovered that another activating NK-cell 
receptor, KIR2DL4, bound to HS in a manner that depended on 3-O-sulfation96 and that 
directly influenced KIR2DL4 signaling and NK-cell function. 
In this study, while investigating possible non-HLA-I ligands for the activating NK-
cell receptor KIR3DS1 through a genome-wide CRISPR/Cas9 knock-out screen, we 
found that KIR3DS1 binds HS. KIR3DS1 binding to HS was completely dependent on 
HS sulfation and upon further testing of other KIRs, we found that the functionally 
divergent inhibitory allotype KIR3DL1 also bound to HS, although to a lesser extent. 
 58 
Similar to other described NK-cell receptor:HS interactions, which occur in cis and in 
trans, these findings uncover a novel KIR3DS1 ligand that may play influential roles in 
NK-cell tuning of receptor signaling and recognition of targets cells. 
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4.3 RESULTS 
4.3.1 KIR3DS1 ligands are expressed in several human cell lines of various 
tissue origins, but are variably expressed on primary cells.  
 In order to screen cell lines for KIR3DS1 ligand expression, we used a KIR3DS1-
Fc fusion chimera consisting of the extracellular domain of KIR3DS1 attached to the Fc 
region of human IgG1 (KIR3DS1-Fc), which confers increased avidity to KIR3DS1 
ligands due to Fc dimerization. Surprisingly, KIR3DS1-Fc bound significantly to all 
human cell lines of T-cell origin (Jurkat), B-cell origin (721.221 and RAJI), monocytic 
origin (THP-1), and erythro-myeloid origin (K562) tested (Fig. 4.1a). To assess 
variability across human donors in transformed primary cells, we assessed KIR3DS1 
ligand expression in various EBV-transformed B-cell lines (BCLs), all of which 
expressed KIR3DS1 ligands although at variable levels (Fig. 4.1b). In addition, upon 
staining peripheral blood lymphocytes isolated from healthy donors, we found that while 
B cells stained positively for KIR3DS1-Fc across donors, although variably, NK cells 
and CD4+ and CD8+ T cells did not (Fig. 4.2a and Fig. 4.2b). 
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Figure 4.1: Human cell lines of various tissue origins express KIR3DS1 ligands. Human cell lines (in 
a) and EBV-transformed B-cell lines (BCLs) from different donors (in b) were stained with KIR3DS1-Fc to 
screen for KIR3DS1 ligands. (Note: Additional peaks in ‘2ry only’ histograms in b are due to variable 
frequencies of IgG+ BCL cells recognized by anti-hIgG(Fc)-PE secondary antibody) 
 
 
Figure 4.2: Peripheral blood lymphocytes show cell-type–dependent KIR3DS1 ligand expression. 
Peripheral blood mononuclear cells were isolated form four different donors, stained with KIR3DS1-Fc 
and lineage markers (anti-CD3, anti-CD4, anti-CD8, anti-CD19, anti-CD56, and anti-CD16 markers). 
Median fluorescence intensity (MdFI) of secondary only (i.e. anti-hIgG(Fc)-PE) staining and KIR3DS1-Fc 
staining is plotted in a, and flow histograms for B cells and NK cells are ploted in b. 
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4.3.2 Genome-wide CRISPR/Cas9 knock-out screen reveals heparan sulfate 
biosynthesis enzymes are critical for KIR3DS1 ligand expression 
Given the widespread distribution of KIR3DS1 ligand expression across various 
human cell lines, we decided to perform a genome-wide CRISPR/Cas9 knock-out 
(GeCKO) screen in the highest expressing cell line—namely, K562 cells—as previously 
described97 (Fig. 4.3a; see details in Materials and Methods). Briefly, ~1.8 × 108 K562 
cells expressing Cas9 were transduced with a single-guide RNA library that individually 
targeted every human gene in individual cells, and were then cultured under selection to 
allow for gene knock-out to occur. 5 × 107 K562-GeCKO cells were then stained with 
KIR3DS1-Fc, followed by a secondary stain with a PE-conjugated anti-human IgG (Fc-
specific) antibody, and a tertiary stain with a magnetic-bead–conjugated anti-PE 
antibody.  The stained K562-GeCKO cells were then passed through a magnetic 
column to bind cells still bearing KIR3DS1 ligand, and flow-through cells were cultured, 
expanded, and then analyzed by flow cytometry. As Fig. 4.3b shows, while almost all 
pre-enriched library cells bound to KIR3DS1-Fc, magnetically depleted flow-through 
cultured cells had ~50% of cells staining very dimly for KIR3DS1-Fc binding. 
In order to determine the genes knocked-out in K562 cells that resulted in loss of 
KIR3DS1-Fc binding, the enriched K562-GeCKO cells were deep sequenced to assess 
for enrichment of specific gRNA sequences (for details, see Materials and Methods). 
Remarkably, sequencing showed that the top nine enriched target genes were enzymes 
involved in HS biosynthesis (Fig. 4.3c and Supplementary Table S4.1). These 
enzymes were directly involved in either HS polysaccharide backbone polymerization 
(i.e. XYLT2, B4GALT7, B3GAT3, EXTL3, EXT1, EXT2), or in the synthesis of precursor 
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molecules needed for HS biosynthesis (i.e. UXS1, UGDH, and PAPSS1) (see 
Illustration 4.1). These results were highly suggestive of HS being necessary for 
KIR3DS1-Fc binding to K562 cells. 
 
Figure 4.3: Genome-wide CRISPR/Cas9 knock-out screen for KIR3DS1 ligands identified heparan 
sulfate biosynthesis genes. (a) Strategy used to magnetically enrich for K562-GeCKO cells that lost 
KIR3DS1 ligand expression. (b) Flow cytometry histograms of K562-GeCKO cells before (top) and after 
(bottom) magnetic enrichment. (c) Graph depicting enrichment of gRNA-targeted genes calculated from 
sequencing analysis of enriched K562-GeCKO cells. CRISPR score calculation is described in Material 
and Methods. Each dot indicates a particular gene, and each alternating section of black and gray dots 
indicates individual chromosomes (chromosomes 1 – 22 and X+Y). Large red dots indicate top nine 
enriched genes (i.e. hits), all of which were involved in HS biosynthesis. 
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Illustration 4.1: Heparan sulfate biosynthesis. Diagram of HS structure and enzymes involved in its 
biosynthesis. GeCKO screening top nine hits are in red bolded text. 
 
 
4.3.3 Surface plasmon resonance confirms KIR3DS1 binding to heparan sulfate 
To confirm our findings, we performed surface plasmon resonance to 
comparatively assess the affinities of KIR3DS1 to different GAGs. Biotinylated 
hyaluronic acid (HA), chondroitin sulfate (CS), and heparan sulfate (HS) were 
immobilized onto individual flow cells of a streptavidin sensor chip at saturating 
concentrations, and KIR3DS1-Fc was flowed over. In concordance with our previous 
results, KIR3DS1-Fc bound significantly to HS, while exhibiting minimal to no binding to 
CS or HA (Fig. 4.4a), thus confirming the interaction between KIR3DS1 and HS. 
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Figure 4.4: KIR3DS1 binds to heparan sulfate. (a) Surface plasmon resonance (SPR) sensogram of 
KIR3DS1-Fc (25 μg/mL) flowed over immobilized heparan sulfate, chondroitin sulfate, or hyaluronic acid 
for 3 min, and then allowed to dissociate by flowing over buffer for 10 min. (b) Flow histogram of 721.221 
cells treated with heparinase II, proteinase K, or no enzyme and stained with KIR3DS1-Fc (25 μg/mL). 
 
 
4.3.4 Elimination of cell-surface heparan sulfate abrogates KIR3DS1-Fc binding 
Next, we investigated whether eliminating cell-surface HS reduced KIR3DS1-Fc 
binding to cell lines that exhibited high KIR3DS1-Fc binding.  To accomplish this, 
721.221 cells were enzymatically treated with heparinase II, proteinase K, or no 
enzyme. Heparinase II cleaves HS at glycosidic bonds between N-sulfated and 
glucuronic or iduronic acid residues, whereas proteinase K (a serine protease) will 
cleave cell-surface proteins including HS proteoglycan protein cores without affecting 
cell integrity. Indeed, enzymatic treatment with both heparinase II and proteinase K 
resulted in a dramatic decrease in KIR3DS1-Fc binding, proving that KIR3DS1-Fc is 
indeed binding to HSPGs (Fig 4.4b). 
To determine whether KIR3DS1 binding to cell-surface HS was dependent on HS 
sulfate moieties, BCLs were cultured in sulfate-free media containing 50 mM sodium 
chlorate (NaClO3). Chlorate (ClO3–) is an inhibitor of 3'-phosphoadenosine-5'-
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phosphosulfate (PAPS) synthase, an enzyme required to generate PAPS, which is the 
universal sulfate donor for all cellular sulfotransferase reactions. In order to assess 
KIR3DS1-Fc binding and HS sulfation content after sulfation inhibition treatment, cells 
were stained at various time points with KIR3DS1-Fc and an anti-HS antibody (clone: 
10E4) that recognizes N-sulfated GlcN residues98. Continuous culture in sulfate-
free/NaClO3-containing media resulted in loss of cell-surface HS sulfation and 
concomitant decrease in KIR3DS1-Fc binding (Fig. 4.5a). This demonstrated that 
KIR3DS1 binding to HS is dependent on the presence of sulfate moieties, which has 
been shown to be the case for other HS-binding proteins93. A separate experiment 
evaluating KIR3DS1 binding after culturing cells in sulfate-free media containing 
different concentrations of ClO3– for 48 h revealed that KIR3DS1-Fc binding was lost 
even at low concentrations of ClO3– (Fig. 4.5b). One report demonstrated that ClO3– 
concentrations of 5–20 mM resulted in selective loss of HS 6-O-sulfate moieties92, 
which may implicate these specifically in KIR3DS1 binding to HS. 
 
Figure 4.5: KIR3DS1 binding to heparan sulfate requires sulfation. (a) Human donor-derived BCL 
cells were cultured for the indicated amounts of time with sulfate-free media containing 50 mM NaClO3 or 
regular media and separately stained with anti-HS antibody (clone: 10E4) and KIR3DS1-Fc (25 μg/mL). 
(b) BCL cells were cultures for 48 h in sulfate-free media containing the indicated concentrations (in mM) 
of NaClO3, and then stained with KIR3DS1-Fc (25 μg/mL). For a and b, flow histograms are presented, 
with gray filled histograms indicating isotype control or secondary only staining (iso).  
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4.3.5 Other D0-domain containing KIRs exhibit HS binding 
Given that protein:HS binding is dominated by electrostatic interactions between 
positively-charged basic residues on proteins and negatively-charged sulfate residues 
on HS, we computationally determined the isoelectric point (pI) of various domains and 
regions of the extracellular portion of several KIRs to roughly assess their potential for 
interacting with HS. We found that the D0 domain of all known KIRs have an pI above 
physiological pH (Fig. 4.6), which signifies that they are net charge positive in the body 
and are more likely binding to HS. However, the D1 domain of all KIRs exhibited an pI 
below physiological pH and thus were net charge negative, with the exception of 
KIR3DS1, which was the only KIR with a D1-domain pI above physiological pH driven 
mainly by a L166R change (relative to KIR3DL1) that is critical to preventing binding to 
HLA-Bw4I80 proteins24. Indeed, a prior study showed that the D0 domain of KIR2DL4 
(which along with KIR2DL5 is the only KIR2D that bears a D0-D2 domain structure) is 
responsible for binding of KIR2DL4 to HS. Thus, we proceeded to assess staining with 
other KIR-Fc constructs on B-cell lines there were or were not cultured in sulfate-
free/NaClO3-containing media. Sulfation inhibition did not affect KIR2DL3-Fc or 
KIR3DL2-Fc staining, but it did significantly decreased KIR3DL1-Fc staining (Fig. 4.7). 
This indicates that KIR3DL1—a highly homologous but functionally divergent allotype of 
KIR3DS1—also binds to HS, although to a lesser extent. Lack of KIR2DL3-Fc staining 
was expected, given the D1-D2 domain structure. However, the lack of KIR3DL2 
binding to HS was surprising, but this may be due to (i) lack of optimal HS 
motifs/moieties   necessary   for   KIR3DS1  binding   on   the   tested   B-cell   lines,   or   
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Figure 4.6: Calculated isoelectric point of KIR domains and regions. The isoelectric point (pI) of 
individual domains and regions of the indicated KIRs was calculated using the ExPASy Compute pI/Mw 
tool99. This was used as a rough estimate of the net charge status of each domain/region. 
 
 
Figure 4.7: KIR-Fc staining of B-cell lines with and without sulfation inhibition. BCL cells from two 
donors (HLA-types indicated, C1* denotes non-KIR2DL3-binding C1 allotype) were cultured for 48 h in 
sulfate-free media containing 50 mM NaClO3 (solid red line histograms) or regular media (solid black line 
histograms), and stained with the indicated KIR-Fc constructs (25 μg/mL each) and anti-hIgG(Fc)-PE 
secondary antibody. Controls were stained with anti-hIgG(Fc)-PE secondary antibody alone (2ry only; gray 
filled histograms). (Note: Additional peaks in ‘2ry only’ histograms are due to presence of IgG+ BCL cells 
recognized by anti-hIgG(Fc)-PE). 
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(ii) repulsive electrostatic interactions between HS and the D1 domain of KIR3DL2, 
which has an unusually low pI and thus a high net negative charge. 
 Having discovered the binding that occurs between KIR3DL1 and HS, we saw 
the opportunity to do a test screen for known HLA-I protein ligands of KIR3DL1 in cell 
lines using KIR3DL1-Fc, which has been notoriously difficult due to what was previously 
called “high background.” To this end, we cultured 721.221 cells and 721.221 cells 
stably transduced with HLA-B*08:01 (a non-ligand), HLA-B*57:01 (a potent KIR3DL1 
ligand), or HLA-B*49:01 (a KIR3DL1 ligand) in regular or sulfate-free/NaClO3-containing 
media and stained with KIR3DL1-Fc. As Fig. 4.8 shows, KIR3DL1-Fc staining of cells 
cultured in regular media showed “high background” with only a small increase in 
staining to HLA-B*57:01 bearing cells, while cells cultured in sulfate-free/NaClO3-
containing media exhibited no staining in non–ligand-bearing cells but retained high 
staining of ligand-bearing cells. This massive increase in the signal-to-noise ratio in this 
proof-of-concept test screen of cell lines is one that may be applied to other “orphan” 
receptors that exhibit binding to HS that is physiologically relevant but obscures cell-
based ligand-screening approaches. 
 
Figure 4.8: KIR3DL1-Fc staining of sulfation-inhibited cells results in significantly better detection 
of HLA-I ligands. 721.221 cells that were untransduced or transduced with HLA-B*08:01, HLA-B*57:01, 
or HLA-B*49:01 were cultured in regular media or in sulfate-free/NaClO3-containing media and stained 
with KIR3DL1-Fc (25 μg/mL).  
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4.4 MATERIALS AND METHODS 
Cell lines and antibodies 
721.221 cell lines (including HLA transductants) were grown in RPMI-1640 
supplemented with 10% fetal bovine serum (Sigma-Aldrich), 2 mM L-glutamine (Gibco), 
100 U/mL penicillin (Gibco), and 100 U/mL streptomycin (Gibco) at 37°C/5% CO2. EBV-
transformed B-cell lines (BCLs) were generated from peripheral blood mononuclear 
cells from donors bearing specific HLA genotypes; BCLs were also grown in the same 
media and conditions as 721.221 cells. The following purified antibodies were used: 
anti-HS-FITC (clone: 10E4, US Biological; used at 1:10 dilution), anti-hIgG(Fc)-PE (Life 
Technologies), anti-CD3 (BioLegend), anti-CD4 (BioLegend), anti-CD8 (BioLegend), 
anti-CD19 (BioLegend), anti-CD56 (clone: HCD56, BioLegend), and anti-CD16 (clone: 
3G8, BioLegend). 
 
KIR-Fc staining 
Cells were stained with KIR-Fc by washing extensively with PBS, incubating for 
30–45 min with 25 μg/mL KIR3DS1-Fc (R&D) diluted in PBS at 4°C while shaking, 
followed by a secondary staining with anti-hlgG(Fc)-PE (Life Technologies) for 30 min at 
4°C while shaking. After staining, cells were washed and fixed using 4% 
paraformaldehyde/PBS (Affymetrix) and flow cytometry analysis was performed on an 
BD LSR II or LSR Fortessa. 
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Genome-wide CRISPR/Cas9 knock-out (GeCKO) screen 
 Screen was performed as previously described in 97. However, methods will be 
briefly described. sgRNA Library Design. The optimized sgRNA library was designed by 
first computationally filtering out potential off-target matches (except for sgRNAs that 
targeted multiple homologs), and also to have high cleavage activity (based on rules 
experimentally determined in another set of experiments). In total, we constructed a 
novel library, containing 178,896 sgRNAs targeting 18,166 protein-coding genes in the 
human consensus CDS (CCDS) and 1,004 non-targeting control sgRNAs. Screen 
procedure. K562 cells were lentivirally transduced with Cas9/eGFP vector. 2.40 × 108 
Cas9-transduced cells were transduced with the viral pool containing the sgRNA library 
to achieve an average 1000-fold coverage of the library after selection with puromycin 
for 7 d. 5 × 107 K562-GeCKO cells were washed in PBS and stained in 1 mL of 25 
μg/mL KIR3DS1-Fc (R&D) for 15 min at 4°C. Cells were then washed with PBS and 
stained with 1 mL of anti-hIgG(Fc)-PE (Life Technologies) diluted 1:50 in PBS. 
Fluorescently labeled cells were washed with PBS and stained with anti-PE Microbeads 
(Miltenyi) following manufacturer’s instructions, except for using twice the recommended 
volumes. Magnetically labelled cells were then depleted in an LD column (Miltenyi) 
following manufacturer’s instructions, and flow-through cells were collected and 
cultured. Screen deconvolution. sgRNA inserts were PCR amplified from 5 million 
genome equivalents of DNA from flow-through cells. The resultant PCR products were 
purified and sequenced on a HiSeq 2500 (Illumina); primer sequences are as follows: 
sgRNA quantification primers:  
F: AATGATACGGCGACCACCGAGATCTAGAATACTGCCATTTGTCTCAAG  
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R: CAAGCAGAAGACGGCATACGAGATCnnnnnnTTTCTTGGGTAGTTTGCAGT 
  TTT  
(nnnnn denotes the sample barcode) 
Illumina sequencing primer: 
CGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTT
CTAGCTCTAAAAC  
Illumina indexing primer: 
TTTCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAATTTTAAAACT
GCAAACTACCCAAGAAA  
Data analysis. Sequencing reads were aligned to the sgRNA library and the abundance 
of each sgRNA was calculated. Gene-based CRISPR scores (CS) were defined as the 
average log2 fold change of all sgRNAs targeting a given gene and calculated for the 
entire screen. To identify enriched genes, the CS distribution was mean-normalized to 
zero. 
 
Sulfation inhibition treatment 
Cells were grown for 48 h (or other time period if specified) in sulfate-
free/NaClO3-containing media, which consisted of custom-made Advanced RPMI-1640 
(Life Technologies) deficient in magnesium sulfate, zinc sulfate, and copper (II) sulfate, 
supplemented with 10% dialyzed FBS (Gibco), 2 mM L-glutamine (Gibco), 100 U/mL 
penicillin (Gibco), 100 U/mL streptomycin (Gibco), 407 μM magnesium chloride (Sigma-
Aldrich), 3.03 μM zinc chloride (Sigma-Aldrich), and 5 nM copper (II) chloride (Sigma-
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Aldrich), and 50 mM sodium chlorate (NaClO3; Sigma-Aldrich) (or other NaClO3 
concentration if specified). 
 
Enzymatic treatment of cell lines 
For surface enzymatic treatment of cells, 2.5 × 105 cells were washed three times 
with PBS, and then incubated in PBS containing 2 U/mL heparinase II (New England 
BioLabs), 1 U/mL proteinase K (New England BioLabs), or no enzyme for 1 h at 
37°C/5% CO2. Cells were then washed in ice-cold PBS and stained as indicated. 
 
Computational analysis of pI 
Isoelectric point analysis was determined by inputing Ig-domain sequences (from 
Cys to Cys) into ExPASy Compute pI/Mw tool, which calculates pI using pKa values of 
amino acids99. The KIR sequences analyzed were obtained from Immuno 
Polymorphism Database (IPD)100,101 and were the following: KIR2DL1*001, 
KIR2DL2*001, KIR2DL3*001, KIR2DL4*001, KIR2DL5A*001, KIR2DS1*002, 
KIR2DS4*001, KIR3DL1*001, KIR3DS1*013, KIR3DL2*001, and KIR3DL3*001. 
 
Surface Plasmon Resonance (SPR) 
SPR measurements were conducted in phosphate-buffered saline (PBS; 
Corning) containing 0.005% v/v surfactant P20 (GE Healthcare) using a Biacore 3000 
system (Biacore AB). To assess binding of various KIR-Fc constructs to various GAGs, 
biotinylated hyaluronate (molecular weight = 29 kDa), biotinylated heparin (molecular 
weight = 18 kDa) and biotinylated chondroitin sulfate (molecular weight = 50 kDa) (all 
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from Creative PEGWorks), were immobilized onto individual flow cells of an SA 
(streptavidin) sensor chip (GE Healthcare) until saturation. A blank flow cell with no 
immobilized ligand was used as a reference flow cell. Injections of 60 μL of KIR-Fc 
constructs diluted in PBS to 25 μg/mL were performed at a flow rate of 20 μL/min, with a 
subsequent 10 min run of buffer to allow sufficient dissociation. Although not presented 
here, regeneration after each injection was achieved with two pulses of 100 μL of 0.2 M 
sodium hydroxide (NaOH) (GE Healthcare) at a flow rate of 100 μL/min. Raw 
sensograms were corrected by double referencing (subtracting from the reference flow 
cell response and from PBS injection response). All experiments were done at standard 
temperature (25°C). 
 
Human Samples and Viruses 
Frozen peripheral blood mononuclear cells (PBMCs) from healthy donors were 
used in this study in accordance to protocols approved by Partners Human Research 
Committee and Institutional Review Board of Massachusetts General Hospital.  
 
Data Acquisition and Analysis 
Flow cytometry data was acquired on BD LSR II or LSR Fortessa and analyzed 
using FlowJo software version 10.1 (FlowJo) and statistical analyses were performed 
using GraphPad Prism 6 (GraphPad Software). 
 
  
 
 
 
 
 
 
 
 
CHAPTER 5: Influence of glycosylation inhibition on the binding 
of KIR3DL1 to HLA-B*57:01 
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5.1 SUMMARY 
Viral infections can affect the glycosylation pattern of glycoproteins involved in 
antiviral immunity. Given the importance of protein glycosylation in immune function, we 
investigated the effect that modulation of the highly conserved HLA class I (HLA-I) N-
glycan has on KIR:HLA-I interactions and NK-cell function. We focused on the 
interaction between HLA-B*57:01 and KIR3DL1, which has been shown to play an 
influential role on the outcome of several human diseases, including HIV-1 infection. 
721.221 cells stably expressing HLA-B*57:01 were treated with a panel of glycosylation 
enzyme inhibitors, and HLA-I expression and KIR3DL1 binding was quantified. In 
addition, the functional outcomes of HLA-B*57:01 N-glycan disruption/modulation on 
KIR3DL1ζ+ Jurkat reporter cells and primary human KIR3DL1+ NK cells was assessed. 
Different glycosylation enzyme inhibitors had varying effects on HLA-B*57:01 
expression and KIR3DL1-Fc binding. The most remarkable effect was that of 
tunicamycin, an inhibitor of the first step of N-glycosylation, which resulted in 
significantly reduced KIR3DL1-Fc binding despite sustained expression of HLA-B*57:01 
on 721.221 cells. This effect was paralleled by decreased activation of KIR3DL1ζ+ 
Jurkat reporter cells, as well as increased degranulation of primary human KIR3DL1+ 
NK cells when encountering tunicamycin-treated HLA-B*57:01-expressing 721.221 
cells. Overall, these results demonstrate that N-glycosylation of HLA-I is important for 
KIR:HLA-I binding and has an impact on NK-cell function. 
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5.2 BACKGROUND 
Natural killer (NK) cells are part of the innate immune system, and serve as a first 
line of defense against intracellular pathogens and malignantly transformed cells. NK 
cells can lyse target cells by secreting perforin and granzyme and by inducing 
FasL:Fas-mediated cell death, but can also activate and recruit other immune cells via 
secretion of pro-inflammatory cytokines and chemokines. The importance of NK-cell 
function is highlighted in the setting of human NK-cell deficiency syndromes, which 
cause increase risk of death in early life due to increased susceptibility to infections with 
commonly encountered viruses and intracellular bacteria (reviewed in 8,102). NK-cell 
activity is regulated via a number of activating and inhibitory receptors (reviewed in 103), 
including killer-cell immunoglobulin-like receptors (KIRs), which recognize human 
leukocyte antigen class I (HLA-I) ligands. Binding of KIRs to HLA-I is determined by the 
respective HLA-I and KIR allotypes, as well as the sequence of the HLA-I presented 
peptides7,104. Whereas binding of inhibitory KIRs to HLA-I molecules results in NK-cell 
inhibition, engagement of activating KIRs or loss of inhibitory KIR binding can lead to 
NK-cell activation105,106. The KIR-HLA interaction has been demonstrated to have an 
important impact on viral infections, including human immunodeficiency virus-1 (HIV-1). 
In HIV-1 positive individuals, KIR3DL1+ NK cells expanded preferentially in the 
presence of HLA-Bw4-80I, the ligand class for KIR3DL1 14,27. 
Protein glycosylation is a post-translational modification occurring in the 
endoplasmatic reticulum (ER) and Golgi apparatus. In multiple enzymatic steps, a 
complex oligosaccharide (i.e. glycan) is synthesized in the ER, transferred to a specific 
receptor sequence on its target protein, and subsequently cropped and remodeled in 
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the ER and Golgi107. In the case of asparagine N-glycosylation, the target amino acid 
sequence on the respective proteins is Asn-X-Ser/Thr, where the glycan is bound to the 
asparagine. It is estimated that over 7,000 distinct glycan structures can be generated in 
mammals108, suggesting a wide range of functional properties, which can be modulated 
by differential glycosylation. The HLA-I glycan at position N86, which is located close to 
the Bw4 motif that is critical for KIR3DL1 binding, is highly conserved and present on all 
classical and non-classical HLA-I genes and allotypes100,109,110. Here we use a panel of 
glycosylation inhibitors to examine the effects of N-glycan modifications on KIR3DL1 
binding to HLA-B*57:01 and their potential effect on NK-cell function, with a more in-
depth characterization of the effect tunicamycin (TUN)—an antibiotic that can 
completely block N-glycosylation in eukaryotic cells by preventing the linkage of the 
glycan to the asparagine111,112—and castanospermine (CSP)—an α-glucosidase I and II 
inhibitor able to inhibit ER glycan trimming that is necessary for the assembly of a fully 
functional glycan112,113. 
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5.3 RESULTS 
5.3.1 Effects of glycosylation enzyme inhibitors on HLA class I expression and 
KIR-Fc binding 
In order to examine the effect of different commercially available glycosylation 
inhibitors (see Illustration 5.1) on KIR:HLA interactions, we examined their effect on 
HLA-B*57:01 expression on HLA-B*57:01-transduced 721.221 cells (also referred to as 
221 cells) and on KIR3DL1-Fc binding to those cells. As shown in Fig. 5.1a and Fig. 
5.1b, inhibitors that targeted Golgi-resident α-mannosidase enzymes (KIF, SWA) 
increased HLA-B*57:01 surface expression, which resulted in increased KIR3DL1-Fc 
binding. The Golgi-resident sialyl transferase inhibitor (STI) tested, however, did not 
result in any appreciable changes in HLA-B*57:01 surface expression or KIR3DL1-Fc 
binding. Inhibitors that targeted ER-resident α-glucosidase II (CSP, DNM), which is an 
enzyme necessary for the last removal of glucose from N-glycans to allow anterograde 
transport to the Golgi, dramatically reduced HLA-B*57:01 surface expression and 
abrogated KIR3DL1-Fc binding. The ER-resident α-glucosidase I-specific inhibitor 
(AUS) minimally increased HLA-B*57:01 surface expression and KIR3DL1-Fc binding. 
However, in the case of TUN, we observed a major decrease in KIR3DL1-Fc binding 
while HLA-B*57:01 surface expression was only slightly increased. Thus, after 
preliminary testing of the effects that several different glycosylation inhibitors had on 
HLA-I surface expression and KIR binding, we decided to focus on TUN, the only 
inhibitor tested that did not decrease HLA-I surface expression but dramatically reduced 
KIR3DL1-Fc binding, and that had the unique function of completely inhibiting addition 
of N-glycans.  
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Illustration 5.1: N-glycan processing and glycosylation inhibitor. Diagram illustrating processing of 
N-glycans in endoplasmic reticulum (ER), Golgi, and their structure at the plasma membrane (PM) (based 
on 114). Glycosylation inhibitors used in this study and the enzymes they target are indicated in red text 
and black blunt-head arrows (for full names of glycosylation inhibitors and target enzymes, see Materials 
and Methods). 
 
 
Figure 5.1: Glycosylation inhibitors screening. Relative median fluorescence intensities (RMdFI) of 
anti-HLA-Bw4 antibody staining (in a) and KIR3DL1-Fc binding (in b) of untransduced 721.221 cells and 
HLA-B*57:01–transduced 721.221 cells treated with a panel of glycosylation inhibitors (n = 2 for each) (for 
details, see Materials and Methods). Black bars indicate glycosylation inhibitors that were used in 
subsequent experiments. 
 
We subsequently performed a titration assay in order to identify the minimal 
amount of glycosylation inhibitors required to observe a strong functional effect on the 
binding of KIR3DL1ζ+ Jurkat cells to HLA-B*57:01-expressing target 721.221 cells (221-
HLA-B*57:01 cells) while keeping target cell death to a minimum. We observed a dose-
dependent effect of both TUN and CSP on KIR3DL1ζ Jurkat cell signaling, with the 
strongest measured effect (i.e. decreased activation of KIR3DL1ζ+ Jurkat cells as 
measured by CD69 expression) corresponding to the highest treatment dose used in 
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previous studies: 0.5 µg/mL of TUN (Supplementary Fig. S5.1a) or 2 mM of CSP 
(Supplementary Fig. S5.1b). Higher doses of glycosylation inhibitors increased cell 
toxicity to a degree that interfered with our assay by causing cell death, while lower 
doses of inhibitors increased signaling of KIR3DL1ζ Jurkat cells after co-incubation, 
indicating a loss of glycosylation inhibition in target cells. Thus, we focused on the 
glycosylation inhibitor TUN at 0.5 µg/mL, the concentration used in previous studies to 
investigating the effects of TUN on HLA-I glycosylation115,116. 
 
5.3.2 HLA class I N-glycan is necessary for KIR3DL1 binding to HLA-B*57:01 
We next sought to quantitatively assess the effects of TUN on HLA-B*57:01 surface 
expression and KIR3DL1-Fc binding. 221-HLA-B*57:01 cells (and wildtype 221 cells as 
control) were treated PBS, CSP or TUN for 24 h, and then stained with anti-Bw4 
antibody, anti-pan-HLA-I antibodies, and KIR3DL1-Fc for flow cytometric assessment. 
TUN treatment of 221-HLA-B*57:01 cells significantly increased HLA-B*57:01 surface 
expression as measured by anti-HLA-Bw4 and anti-pan-HLA-I antibody staining (1.5-
fold HLA-Bw4 MdFI increase, p < 0.02; 2.0-fold W6/32 MdFI increase, p < 0.001)   (Fig. 
5.2   and   Fig. 5.3a).   In contrast, co-incubation with CSP significantly decreased HLA-I  
 
pan-HLA-I (W6/32)
surface staining
Figure 5.2: TUN treatment of 721.221-HLA-B*57:01 
cells increases HLA-I surface expression. Relative 
median fluorescence intensity (RMdFI) of anti-pan-
HLA-I (W6/32) staining was calculated for 721.221 cells 
and 721.221-HLA-B*57:01 cells treated with TUN, CSP, 
or untreated 
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expression (2.1-fold HLA-Bw4 MdFI decrease, p < 0.02; 1.7-fold W6/32 MdFI decrease,  
p < 0.05). Since glycosylation inhibition similarly affected staining with anti-HLA-Bw4 
and anti-pan-HLA-I antibody, which only recognizes folded HLA-I complexes bound to 
β2m, we believe that HLA- B*57:01 proteins expressed at the cell surface were folded 
complexes of HLA-B*57:01 and β2-miroglobulin and not free heavy chains. 
 
 
Figure 5.3: N-glycosylation inhibition increases HLA-B*57:01 surface expression while abrogating 
KIR3DL1-Fc binding. Anti-HLA-Bw4 antibody staining (in a) and KIR3DL1-Fc staining (in b) was 
performed on 721.221-HLA-B*57:01 cells treated with TUN, CSP, or untreated, and untransduced 
721.221 cells. Representative histograms are on left panels and data representing n = 5 technical 
replicates are presented as bar graphs on right panels. One-way ANOVA with Dunnette multiple 
comparisons test was performed (*, p < 0.05; ***, p < 0.001). 
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Sustained expression of HLA-B*57:01 on 221-B*57:01 cells following TUN 
treatment enabled assessment of the consequences of HLA-I de-glycosylation on 
KIR3DL1 binding to HLA-B*57:01. Despite enhancement of overall HLA-B*57:01 
expression, TUN treatment abrogated KIR3DL1-Fc binding. Cells treated with TUN 
bound KIR3DL1-Fc significantly less than untreated cells (4.7-fold KIR3DL1-Fc MdFI 
decrease, p < 0.001). 221-HLA-B*57:01 cells treated with CSP also exhibited reduced 
KIR3DL1-Fc binding (6.9-fold KIR3DL1-Fc MdFI decrease, p < 0.001) (Fig. 5.3b), which 
was expected given the reduced surface stating of HLA-B*57:01 on CSP-treated cells. 
Taken together, these data demonstrate that the presence of N-glycosylation is critical 
for KIR3DL1 binding to HLA-B*57:01.  
 
5.3.3 HLA class I N-glycan is necessary for functional signaling through 
KIR3DL1 in KIR3DL1ζ+ Jurkat cells 
Jurkat reporter cells stably expressing a chimeric receptor of the extracellular and 
transmembrane domain of KIR3DL1 fused to the cytoplasmic tail of CD3ζ, referred to as 
‘KIR3DL1ζ’, was employed to assess the functional consequences of glycosylation 
inhibition. KIR3DL1ζ engagement of its ligand HLA-B*57:01 results in an activating 
signal that triggers CD69 expression. Jurkat cells were gated by size, CD3 expression, 
and KIR3DL1ζ expression. Cells that were CD3+KIR3DL1ζ– were, by definition, 
untransduced and thus were used as an internal negative control.  
KIR3DL1ζ+ Jurkat reporter cells were potently stimulated by 221-HLA-B*57:01 
cells. However, stimulation of KIR3DL1ζ+ Jurkat cells was abrogated by pre-treatment of 
221-HLA-B*57:01 cells with TUN (4.4-fold CD69 MdFI decrease, p < 0.001) (Fig. 5.4a 
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and Fig. 5.4c). As expected, 221-HLA-B*08:01 cells and untransduced 221 cells did not 
stimulate KIR3DL1ζ+ Jurkat cells, and treatment with TUN had no effect (Fig. 5.4a). 
Untransduced Jurkat cells were not activated after co-incubation with any of the tested 
target cells regardless of TUN treatment (Fig. 5.4b and Fig. 5.4c). These results 
demonstrate that lack of N-glycosylation abrogates KIR3DL1:HLA-B*57:01 binding, and 
this has direct functional consequences on KIR3DL1ζ+ Jurkat cell function.  
 
Figure 5.4: TUN treatment of 721.221-HLA-B*57:01 cells abrogates triggering of KIR3DL1ζ+ Jurkat 
reporter cells. Reporter activity of KIR3DL1ζ+ (in a) and untransduced (in b) Jurkat reporter cells was 
measured by calculating relative median fluorescence intensity (RMdFI) of CD69 relative to unstimulated 
Jurkat cells. Reporter assay was carried out for 2 h at a repoter-to-target cell ratio = 1:1.  Bar graphs in a 
and b show the mean ± standard deviation of n = 10 replicates, whereas representative flow histograms 
are presented in c.  
 
 
5.3.4 Primary human KIR3DL1+ NK cells are ‘de-repressed’ upon encountering 
tunicamycin-treated HLA-B*57:01+ target cells. 
We subsequently examined the effect of TUN on the interaction between primary 
human KIR3DL1+ NK cells and HLA-B*57:01+ target cells by assessing degranulation in 
KIR3DL1+ NK-cell clones co-incubated with TUN-treated or untreated 221-HLA-B*57:01 
cells. NK cell clones were gated for FSC, SSC and expression of CD56, CD16, 
KIR3DL1 and CD107a (Fig. 5.5a). KIR3DL1+ NK cells exposed to 221 cells 
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degranulated extensively (74.47% ± 2.20% CD107a+), but were significantly suppressed 
when exposed to 221-HLA-B*57:01 cells (27.20% ± 0.7% CD107a+, 2.7-fold decrease 
compared to the 221 samples, p < 0.0001), which was still significantly higher than 
unstimulated NK cells (0.46% ± 0.11% CD107a+) (Fig. 5.5b). However, TUN pre-
treatment of 221-HLA-B*57:01 cells resulted in a significant increase in degranulation 
(38.53% ± 1.37% CD107a+, 1.4-fold increase compared to 221-HLA-B*57:01, p < 
0.0001) compared to untreated 221-HLA-B*57:01 cells. KIR3DL1– NK cells exposed to 
221 cells (80.57% ± 1.87%) degranulated significantly more than when exposed to 221-
B*57:01 cells (66.7% ± 1.05%, 1.2-fold decrease compared to 221, p = 0.0007) (Fig. 
5.5c). Co-incubation of target cells with TUN had no significant effect on KIR3DL1– NK 
cells (221: p = 0.6874; 221-B57: p = 0.1629). Thus, TUN treatment of 221-HLA-B*57:01 
cells ‘de-repressed’ KIR3DL1+ NK cells that would normally have been suppressed by 
KIR3DL1 engagement of N-glycosylated HLA-B*57:01 proteins, suggesting a critical 
and functional role for HLA-I N-glycans in KIR binding and primary NK-cell function 
modulation. 
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Figure 5.5: KIR3DL1+ NK-cell clones are disinhibited by TUN treatment of 721.221-HLA-B*57:01 
cells. (a) Representative flow plots of a KIR3DL1+ NK-cell clone degranulating in response to TUN-pre-
treated and untreated 721.221 and 721.221-HLA-B*57:01 cells. Degranulation was carried out for 2 h in 
the presence of fluorophore-conjugated anti-CD107a antibody before staining for surface NK-cell 
receptors. (b, c) Bar graphs show frequency of degranulating KIR3DL1+ (in b) and KIR3DL1– (in c) NK-
cell clones co-incubated with the indicated target cells. Data represented mean ± standard deviation of n 
= 3 technical replicates. One-way ANOVE with Dunnett multiple comparisons test was performed (ns, 
non-significant; ***, p < 0.001; *, p < 0.05). 
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5.4 MATERIALS AND METHODS 
Target Cells 
HLA-I-deficient 721.221 cells (also referred to as ‘221 cells’) stably expressing 
HLA-B*08:01 or HLA-B*57:01 were provided by Christian Brander (Ragon Institute of 
MGH, MIT and Harvard, Cambridge, MA). All cells were cultured at 37°C with 5% CO2 
in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) (Biochrom AG), 2500 U/mL penicillin and 2500 µg/mL streptomycin 
(Sigma-Aldrich) unless stated otherwise; this media was referred to as ‘R10’. 
 
Glycosylation inhibition screening and titration 
Glycosylation inhibition was performed by incubating target cells for 24 h at 
37°C/5%CO2 in R10 supplemented with different glycosylation inhibitors: 5 mM  of 1-
deoxynojirimycin (DNM; Tocris Bioscience), an α-glucosidase II > I inhibitor; 500 µM of 
australine (AUS; Santa Cruz Biotechnology), an α-glucosidase I inhibitor; 2 mM of 
castanospermine (CSP; Tocris Bioscience), an α-glucosidase I and II inhibitor; 100 µM 
of kifunensine (KIF; Tocris Bioscience), an α-mannosidase I inhibitor; 500 µM of 3Fax-
peracetyl-Neu5Ac (STI; EMD Millipore), a sialyltransferase inhibitor; 100 µM of 
swainsonine (SWA; Tocris Bioscience), an α-mannosidase II and lysosomal α-
mannosidase inhibitor; 0.5 µg/mL of tunicamycin (TUN; Sigma-Aldrich), a GlcNAc 
phosphotransferase inhibitor; or phosphate buffered saline (PBS) as negative control. 
Optimal concentrations of glycosylation inhibitors were determined by using effective 
concentrations reported in the literature as well as lower and higher doses. Readouts 
measured were HLA expression, KIR3DL1-Fc binding, CD69 expression of KIR3DL1ζ+ 
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Jurkat cells, or degranulation of KIR3DL1+ NK cells after staining or co-incubating with 
glycosylation-inhibitor–pre-treated untransduced or HLA-transduced 721.221 target 
cells. 
 
Quantification of HLA-I expression and KIR3DL1 binding 
For HLA-I cell surface expression, target 221 cells (1.5 × 105 per well) were 
treated with TUN, CSP, or PBS for 24 h. After washing, cells were stained with either 
biotinylated anti-HLA-Bw4 antibody (One Lambda) followed by secondary staining with 
streptavidin-BV421 (BioLegend), or anti-pan-HLA-I-PE antibody (clone: W6/32) 
(BioLegend). For KIR-Fc binding assessment, target cells (1.5 × 105 per well) were 
grown for 48 h in modified media prior to KIR-Fc staining to reduce background staining. 
Modified media consisted of custom-made Advanced RPMI-1640 (Life Technologies) 
deficient in magnesium sulfate, zinc sulfate, and copper (II) sulfate supplemented with 
10% dialyzed FBS (Gibco), 2 mM L-glutamine (Gibco), 100 U/mL penicillin (Gibco), 100 
U/mL streptomycin (Gibco), 407 μM magnesium chloride (Sigma-Aldrich), 3.03 μM zinc 
chloride (Sigma-Aldrich), and 5 nM copper (II) chloride (Sigma-Aldrich), which was 
mixed with 150 mM sodium chlorate (Sigma-Aldrich) at a 5:1 volume ratio. During the 
last 24 h, TUN, CSP or PBS were added to the medium. After washing, cells were 
stained for 45 min with 25 μg/mL KIR3DL1-Fc (R&D) at 4°C while shaking, followed by 
a secondary staining with anti-hlgG(Fc)-PE (Life Technologies) for 30 min at 4°C while 
shaking. After staining, cells were fixed using 4% paraformaldehyde/PBS (Affymetrix) 
and flow cytometry analysis was performed on an LSR-II (BD). 
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Jurkat reporter cell assay 
Jurkat cells (clone E6.1; ATCC) were cultivated in R10 medium. 24 h before 
performing experiments, 10% fetal bovine serum was added to the culture to reduce 
background activation. Jurkat cells stably expressing KIR3DL1ζ, a chimeric receptor 
composed of the extracellular and transmembrane domains of KIR3DL1 linked to the 
cytoplasmic tail of CD3ζ, which we denote as ‘KIR3DL1ζ‘, were produced via lentiviral 
transduction/transfection. Briefly, gene constructs were designed and ordered via 
GeneArt (Life Technologies), and cloned into a lentiviral transfer vector containing an 
SFFV promotor and IRES-driven puromycin resistance. HEK293T cells (ATCC) were 
transfected with a VSV-G envelope vector (pHEF-VSVG, NIH AIDS Reagent Program), 
HIV-1 gag-pol packaging vector (psPAX2, NIH AIDS Reagent Program), and the 
transfer vector containing KIR3DL1ζ. Lentivirus-containing supernatants were harvested 
72 h after transfection and used to transduce Jurkat cells, which were subsequently 
selected in R10 containing 1 μg/mL puromycin and sorted for gene expression by flow 
cytometry. In these KIR3DL1ζ+ Jurkat cells, ligand engagement by KIR3DL1ζ results in 
an activating signal that triggers CD69 expression, making them a suitable reporter cell 
system. Prior to co-incubation with target cells, Jurkat cells were cultured for 24 h in 
R10 medium supplemented with an additional 10% fetal bovine serum. 221 cells 
expressing HLA-B*08:01, HLA-B*57:01, or no HLA-I underwent glycosylation inhibition 
and were washed twice.  Target cells were washed to remove glycosylation inhibitors 
and then co-incubated with either KIR3DL1ζ+ or untransduced Jurkat cells at a reporter-
to-target cell ratio of 1:1 (1 × 105 each) for 2.5 h at 37°C/5%CO2. Cells were then 
washed, stained with anti-CD3-PerCP-Cy5.5, anti-CD69-BV421, and anti-KIR3DL1-
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APC (all from BD) for 30 min at 4°C, fixed with 4% paraformaldehyde/PBS, and 
analyzed on an LSR-Fortessa (BD). KIR3DL1ζ-transduced Jurkat cells were gated for 
KIR3DL1 expression, classifying them either as KIR3DL1ζlow, KIR3DL1ζdim or 
KIR3DL1ζbright.  
 
NK cell cloning and degranulation assay 
Primary human NK cells isolated from peripheral blood mononuclear cells 
(PBMCs) of healthy donors were cloned by limiting dilution in the presence of feeders 
and maintained in NK cell cloning medium consisting of R10 supplemented with 5% 
human serum (Sigma-Aldrich), 1X MEM-NEAA (Gibco), 1X sodium pyruvate (Gibco), 
100ug/mL Kanamycin, 200 U/mL IL-2 (AIDS Reagent Program, NIH) using a protocol 
adapted from a previously reported method (22). Briefly, NK cells were isolated from 
peripheral blood mononuclear cells (PBMCs) from a KIR3DL1+ HLA-Bw4+ donor via 
magnetic negative selection (NK cell isolation kit from Miltenyi), added to a mix of 
irradiated feeders consisting of freshly isolated allogeneic (PBMCs) combined with log-
phase-growth RPMI 8866 cells (Sigma-Aldrich) at a 10:1 ratio in cloning medium 
containing 1 μg/mL phytohaemagglutinin (PHA; Fisher) and mixed thoroughly before 
plating at 100 µL/well (0.5 NK cell/well) in 96-well plates and incubated for 14 days at 
37°C/5% CO2. After 14 days, wells that had outgrowth of cells were transferred to 48-
well plates and maintained in NK cell cloning medium with frequent media exchange 
(approximately every 3 days). Cells were phenotyped by flow cytometry to assess NK 
cell marker (e.g. CD56 and CD16) and KIR3DL1 expression. Degranulation assays 
were performed by co-incubating 5 × 104 NK cells with 2.5 × 105 target cells (effector-to-
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target cell ratio of 1:5) in 200 µL of R10 containing 3 µL of anti-CD107a-PE-Cy7 
antibody (BioLegend) for 2 h at 37°C/5% CO2, and subsequently staining with anti-
CD56-BV605 and anti-CD16-BV785 antibodies (both from BioLegend) for 30 min at 
4°C, and then fixed with 4% paraformaldehyde/PBS. Flow cytometric analysis was 
performed on a BD LSRFortessa. 
 
Ethics 
PBMCs from healthy donors were obtained and frozen after obtaining written 
informed consent following procedures approved by the Partners Human Research 
Committee (ethics committee) and the Institutional Review Board of Massachusetts 
General Hospital. HLA-I types of selected human samples were determined prior to this 
study by high-resolution HLA-I typing performed at the HLA-typing laboratory of the 
National Cancer Institute, National Institutes of Health. KIR types were determined prior 
to this study by Sanger sequencing in the laboratory of Mary Carrington. 
 
Statistics 
Flow data was analyzed in FlowJo v10 (FlowJo LLC, Ashland, Oregon). 
Statistical analyses were performed using GraphPad Prism 6.0c (GraphPad Software 
Inc., La Jolla, California, USA). Normality tests (Kolmogorov-Smirnov test with Dallal-
Wilkinson-Lilliefor P value) were performed on all data sets, statistical significance was 
calculated via one-way ANOVA, and multiple comparisons were corrected using 
Tukeys’s test if not stated otherwise. All graphs show mean ± SD if not stated otherwise 
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in the figure legends. Significance levels were defined as the following: *, p < 0.05; **, p 
< 0.01; ***, p < 0.001; and ****, p < 0.0001. 
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6.1 KIR3DS1 binds HLA-F 
6.1.1 KIR3DS1 binding to HLA-F is functionally and physiologically relevant 
The activating NK-cell receptor KIR3DS1 has been associated with the outcome 
of viral infections31,42,49 including HIV-116,19, autoimmune disorders41, transplantation38–
40
, and cancer development/treatment33,34,36,37. However, the precise nature of a ligand 
that can account for such broad biological effects has remained—although extensively 
studied—unknown. Here, we identified HLA-F OCs as ligands for KIR3DS1, and 
showed that HLA-F OCs trigger polyfunctional responses in primary human NK cells 
through KIR3DS1. It was further demonstrated that KIR3DS1 ligands, in particular HLA-
F, are expressed on the surface of activated CD4+ T cells. However, upon HIV-1 
infection of activated CD4+ T cells, KIR3DS1 ligand surface expression was 
downregulated, yet this did not abrogate efficient suppression of viral replication by co-
cultured KIR3DS1+ NK cells in vitro. Our findings provide novel and significant insight 
into the protective effect of KIR3DS1 in HIV-1 infection, and provide an explanation for 
the widespread influence of KIR3DS1 in human disease. 
 
6.1.2 KIR3DS1 binding to HLA-F is not unique but is evolutionarily conserved 
Differential binding of KIR3DS1 and the other lineage II KIRs3 to HLA-F is 
remarkable from a structural homology perspective, and is shared with other related 
receptors.  The leukocyte immunoglobulin-like receptor (LILR) family is another group of 
HLA-I-binding receptors found near the KIR locus in the leukocyte receptor complex 
(LRC)117. The LILR family has inhibitory members (i.e. LILRBs) that bind HLA-I 
complexes and activating members (i.e. LILRAs) that bind HLA-I OCs55,118, a property 
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that our data suggests is partially shared with KIRs; two members in particular, LILRB1 
and LILRB2, exhibit robust binding to HLA-F119. From this present study, we find that all 
lineage II KIRs bind HLA-F OCs, with KIR3DS1 exhibiting the highest affinity binding to 
and the most potent functional signaling capacity upon engagement of HLA-F OCs on 
target cells. KIR3DL2, which has been previously shown to bind HLA-F OCs120, shares 
~86% extracellular domain sequence identity with KIR3DS1, which readily explains 
differences in binding affinity. However, it is remarkable that despite >97% extracellular 
domain sequence identity between KIR3DS1 and KIR3DL1, KIR3DS1 exhibits 
significantly higher-affinity binding to HLA-F OCs than KIR3DL1, whereas KIR3DL1 (but 
not KIR3DS1) bears high-affinity binding to HLA-Bw4 ligands. Structural studies indicate 
that the few amino acid differences between KIR3DS1 and KIR3DL1 occur at sites 
critical for HLA binding24. From an evolutionary standpoint, these different ligand-binding 
profiles of KIR3DL1 towards various HLA-Bw4 allotypes and KIR3DS1 towards HLA-F, 
which is also monomorphic with one predominant allele (HLA-F*01:01 at >95% 
frequency)121, provide an explanation for the high polymorphicity of KIR3DL1 and the 
relative monomorphicity of KIR3DS1. 
 
6.1.3 KIR3DS1:HLA-F axis may be a mode of detecting “stressed self” similar 
to NKG2D and its ligands 
This newly identified KIR3DS1:HLA-F axis has many similarities to the well-
known stress-induced NKG2D:MIC-A/B axis, even in the context of HIV-1 infection. 
Although it is less well-studied, HLA-F bears unique and distinguishing characteristics 
that separates it from all other HLA-I genes. According to a study examining the genesis 
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and architectural evolution of the MHC locus, HLA-F acted as the ancestral progenitor 
to today’s HLA-I and MIC-A/B genes122. HLA-F retains features that are similar to MIC-
A/B genes, including being peptide-devoid and being able to refold in vitro with and 
without β2m, indicating its unique ability to be stable as an OC57, in line with data 
presented here. In agreement with previous studies62,123, our data show that HLA-F 
OCs are expressed on the surface of activated CD4+ T cells. Also, although only 
partially assessed in this study with B-cell lines, several studies have indicated that 
cancers of various tissue origins aberrantly express HLA-F123,124. Additionally, HIV-1 
infection of CD4+ T cells increased transcription of HLA-F but reduced KIR3DS1 ligand 
expression, particularly in late-infected cells, which might suggest the employment of an 
immune-evasion strategy, potentially through the downregulation of HLA-F by HIV-1 
accessory proteins, similar to what has been described for HIV-1 Nef for HLA-A and 
HLA-B125–127 and NKG2D ligands including MIC-A128, but also HIV-1 Vpu for HLA-G129 
and HLA-C130. Our findings are therefore reminiscent of the up-regulation of the NKG2D 
ligands MIC-A and MIC-B on the surface of activated T cells, virally infected cells, and 
transformed cells, which are downregulated in the context of HIV-1 by the actions of the 
accessory protein Nef128.  
HLA-F expression is tightly regulated131, with restricted tissue expression119,123 
and predominant localization to the endoplasmic reticulum. This indicates that HLA-F 
expression might serve as a marker for specific kinds of cell stress, such as 
endoplasmic reticulum stress. Similar to the phenomenon seen for MIC-A132,133, HLA-F 
can be a target for humoral immune responses, as was shown in one study that 
reported the presence of anti-HLA-F antibodies in the sera of cancer patients but not 
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healthy controls124. Collectively, these studies underscore a critical role of HLA-F 
expression in human diseases, and our data demonstrating that KIR3DS1 recognizes 
HLA-F OCs uncovers a previously unknown mechanism of innate immune surveillance 
of stressed cells. 
 
6.1.4 Previous associations of KIR3DS1 to HLA-Bw4I80 are likely driven by 
KIR3DL1 
KIR3DS1 binding to HLA-F expounds its widespread influence on human 
diseases, but it does not fully explain the well-known association of KIR3DS1 to HIV-1 
disease control described only for HLA-Bw4+ patients. Several studies have confirmed, 
however, that in the context of HIV-1 infection, presence of KIR3DS1 and KIR3DL1 
together associate with decreased viremia, delayed progression to AIDS, and better in-
vitro viral inhibition by NK cells in patient bearing HLA-Bw4I8019,134. This protective 
compound genotype can be explained by independent but functionally synergistic 
effects of KIR3DS1:HLA-F and KIR3DL1:HLA-Bw4 interactions, the latter of which has 
independently been linked to delayed HIV-1 disease progression18. Of note, a single 
recent study demonstrated KIR3DS1 binding to HLA-B*57:01 presenting two HIV-1 
peptides that arose from an exhaustive screen of various viral peptide databases25. 
However, it is not clear whether this interaction has real functional consequences, or 
represents an exceptional case where a peptide can overcome KIR3DS1 mutations that 
normally abrogate HLA-Bw4 binding. Indeed, KIR3DS1 has been linked to many other 
human diseases without association to HLA-Bw431,34,36,40,42, suggesting that KIR3DS1 
exerts disease modulatory effects independent of HLA-Bw4. 
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6.1.5 KIR3DS1:HLA-F interactions may play roles in both elimination of 
pathologically altered cells and regulation of adaptive immunity 
KIR3DS1:HLA-F interactions between NK cells and pathologically altered target 
cells would incur the well-known innate function of NK cells to recognize and eliminate 
target cells expressing “stressed self” ligands. This is supported by our in-vitro co-
culture assay, which showed that NK cells singly expressing KIR3DS1 are more 
effective at suppressing HIV-1 replication in autologous CD4+ T cells as compared to 
KIR3DS1– NK cells. In addition, our data show that KIR3DS1:HLA-F interactions elicit 
NK-cell production of antiviral and pro-inflammatory cytokines such as IFN-γ, TNF-α, 
and MIP-1β, which would have pleiotropic effects on immune responses. Furthermore, 
KIR3DS1:HLA-F interactions between NK cells and activated CD4+ T cells would also 
suggest a means of NK cell-mediated adaptive immune regulation. This notion is 
warranted by previous work in LCMV infection mouse models, which show that NK cells 
regulate adaptive immunity by killing activated CD4+ T cells, resulting in decreased 
immunopathology43.  Thus, KIR3DS1 recognition of HLA-F OCs expressed on activated 
immune cells and/or infected target cells provides a mechanistic link between KIR3DS1 
and HIV-1 disease progression, and will also have relevance for the pathogenesis of 
other infectious diseases, autoimmune disorders, and tumor immune-surveillance. 
In conclusion, the novel interaction between the activating NK-cell receptor 
KIR3DS1 and HLA-F OCs described here uncovers a previously unknown mechanism 
of target cell recognition by NK cells. Further studies will be required to determine how 
KIR3DS1:HLA-F interactions play a role in NK cell-mediated regulation of immunity 
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and/or elimination of pathologically altered target cells. Each of the clinical diseases 
KIR3DS1 has been implicated in, including autoimmune disorders41, transplantation 
outcomes38–40, cancer development/clearance33,34,36,37, and viral infections16,19,31,42,49, 
offers a variety of prospects to exploit KIR3DS1:HLA-F interactions therapeutically. 
 
6.2 KIR3DS1 binds heparan sulfate 
6.2.1 KIR3DS1 binding to HS can be explained through electrostatic 
interactions and may be applicable to other KIRs.  
 In this study, we found through a genome-wide CRISPR/Cas9 knock-out screen 
that HS is a ligand for KIR3DS1, which we confirmed biochemically and on primary cells 
and cell lines. KIR3DS1 domain analysis revealed that in contrast to other KIRs, each of 
its domains is predicted to be net charge positive at physiological pH. This is consistent 
with the interaction between KIR3DS1 and HS, which is usually electrostatically driven 
for other HS-binding proteins. The fact that KIR3DL1, a highly homologous inhibitory 
allotype with >97% extracellular domain protein sequence identity, also bound to HS 
although to a lesser extent is also unsurprising, as the critical L166R mutation that 
abrogates KIR3DS1 binding to HLA-Bw4I80 proteins24 is also critical for conferring a net 
positive charge to its D1 domain. Indeed, whereas KIR2DL4 was previously shown to 
interact with HS via its net positively charged D0 domain96, other potential HS-
interacting receptors not tested here are the “orphan” inhibitory NK-cell receptors 
KIR2DL5 and KIR3DL3, both of which contain a net positively charged D0 domain. 
Interestingly, in the case of KIR2DL5, KIR2DL5-Fc fusion proteins have been described 
to exhibit “dull staining of, essentially, every human cell line…independent of the cells 
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HLA allotypes”135. To explain this, we believe it is very likely that KIR2DL5 also binds to 
HS, although this needs to be formally tested. Of particular practical interest was the 
finding that with sulfation inhibition treatment, the ability to detect binding of KIRs to 
HLA-I ligands was significantly increased due to the elimination of HS-interactions that 
obscure detection of binding (i.e. reduce signal-to-noise ratio). This may also prove to 
be a very useful adjunctive strategy for investigators seeking to perform cell-based 
screens for protein ligands of HS-interacting proteins. 
 
6.2.2 NK-cell “heparanosome” may regulate KIR3DS1 and other NK-cell 
receptors in cis 
 Cis interactions between HS and NK-cell receptors like KIR2DL4 have been 
shown to cause clustering and block trans interactions, allowing for another level of 
tunable control over NK-cell–receptor signaling96. Interestingly, KIR3DS1-Fc did not 
bind to primary human NK cells from healthy donors, which may suggest that at 
baseline, cis interactions between KIR3DS1 and HS do not occur. However, it is 
conceivable that upon cellular activation, NK cells alter the composition of cell-surface 
HS—also referred to as the “heparanosome”—to alter receptor functionality. This is 
particularly interesting in light of the altered functionality in NK cells that express CD57, 
which is an epitope comprising a surface-expressed glucuronic acid 3-O-sulfate moiety 
produced by induction of B3GAT1. Expression of CD57 has been shown to correlate 
with a more “mature” NK-cell phenotype characterized by poor proliferative capacity, 
poor cytokine responsiveness, and increased sensitivity to CD16-mediated activation. 
The effect of induction or modulation of heparan sulfate biosynthetic enzymes on NK-
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cell function, however, has not been appreciably studied, but in light of these data, may 
be highly influential on the signaling capacity of receptors such as KIR3DS1 and overall 
NK-cell function. 
 
6.2.3 KIR3DS1:HS interactions between NK and target cells may play a role in 
cancer immunesurveillance 
 The binding of D0-domain–containing KIRs to HS can influence NK-cell function 
depending on whether these interactions occurs in cis and/or in trans. Interactions of 
KIRs and other NK-cell receptors in trans with target-cell–expressed HS would incur an 
understudied mode of target cell recognition mediated by protein-carbohydrate 
interactions. Indeed, specific cell types (and cellular contexts) exhibit precise 
heparanosome signatures that encode for a variety of motifs for HS-binding proteins to 
interact with. Cancer cells of various tissue origins significantly alter heparan sulfate 
biosynthesis genes to alter cell-surface HS, which has been shown to play a role in 
tumorigenesis. One mode of modulation that is widely found in cancer cells is 
methylation-associated silencing of HS sulfotransferase genes136, which has been found 
to correlate with cancer progression and poor prognosis137. Although various biological 
processes that are hallmarks of cancer138 (such as tissue invasion and altered growth 
factor signaling) are undoubtedly affected, it is conceivable that this may also contribute 
to immune evasion via decreased recognition by HS-binding NK-cell receptors. 
The role of KIR3DS1:HS interactions in cancer immunosurveillance is of 
particular interest because it is an activating receptor associated to the outcome of 
various cancers33–36. Similar to NCR binding to specific HS motifs, it is possible that 
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KIR3DS1 and other KIRs have specific motifs or binding domains on HS they can dock 
onto, although a more careful analysis over-expressing and knocking-out specific 
sulfotransferase genes will be required for this kind of study. Understanding target-cell–
expressed HS motifs recognized by NK-cell receptors, as well as their potential to be 
eliminated in cancer cells through the silencing of HS biosynthetic enzymes to evade 
NK cell recognition, is an area of study warranting further investigation. In the realm of 
autoimmunity, the use of HS mimetics that block these interactions may also be very 
useful, such as in the case of ankylosing spondylitis, which has been shown to be 
strongly associated to particular alleles of KIR3DS1 and KIR3DL1. 
Ultimately, it is clear that protein-carbohydrate interactions play a crucial role in 
NK-cell function, and studies that further explore the extent and specificity of these 
interactions will allow for the development of therapies that modulate these interactions, 
particularly in the context of cancer and autoimmunity. 
 
6.3 KIR3DL1 binding to HLA-B*57:01 is N-glycosylation dependent 
6.3.1 Presence of N86 HLA-I N-glycan is necessary for KIR3DL1 to bind to and 
signal upon engagement of HLA-B*57:01 
N-glycosylation is a critical step in post-translational protein modification with 
functional importance that is not yet fully understood. In the case of all HLA-I allotypes, 
a single, highly conserved N-glycosylation site is located at position N86100,109,110, in 
close proximity to the highly polymorphic motif spanning from amino acids 77 to 83, 
which constitutes the Bw4 motif in HLA-Bw4 allotypes and is critical for KIR3DL1 
binding to these24. We therefore hypothesized that HLA-I N-glycosylation can modulate 
 102 
binding between HLA-Bw4 proteins and KIR3DL1. To test this hypothesis, we employed 
a panel of glycosylation enzyme inhibitors to modify or eliminate N-glycan structures in 
HLA-B*57:01-expressing cells and assessed HLA-B*57:01 expression and binding to 
KIR3DL1. We demonstrate that presence of the N-glycan on HLA-B*57:01 is critical for 
binding to KIR3DL1, and that inhibition of N-glycosylation in target cells can have 
functional consequences on KIR3DL1+ cell lines and primary KIR3DL1+ NK cells. 
Inhibition of different glycosylation enzymes led to different effects in terms of 
HLA-B*57:01 expression and KIR3DL1 binding. The most striking effect was observed 
for TUN-induced inhibition of N-glycosylation, which increased cell surface expression 
of HLA-B*57:01 while abrogating KIR3DL1 binding. This was in contrast to all other 
inhibitors, which either increased (for KIF, SWA), decreased (for CSP, DNM), or did not 
significantly alter (for AUS, STI) HLA-B*57:01 surface expression in a manner that 
correlated with increased, decreased, or unchanged KIR3DL1 binding, respectively. 
TUN-induced increase in HLA-B*57:01 surface expression was measured using two 
different antibodies—anti-HLA-Bw4 (clone: Bw4) and anti-pan-HLA-I (clone: W6/32)—
demonstrating that the Bw4 motif, which is situated next to the N-glycosylation site, is 
still recognized, and that the HLA-I molecule is expressed as a complex bound to β2-
microglobulin. We further demonstrated that loss of KIR3DL1-Fc binding to TUN-treated 
HLA-B*57:01+ target cells matched functional readouts using KIR3DL1ζ+ Jurkat reporter 
cells and primary human KIR3DL1+ NK cells. KIR3DL1ζ+ Jurkat cells were stimulated by 
co-incubation with 221-HLA:B*57:01 cells, yet this stimulation was almost completely 
abrogated by treating target cells with TUN prior to co-incubation. In line with this, 
primary KIR3DL1+ NK cells were potently inhibited by 221-HLA-B*57:01 cells, but were 
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‘de-repressed’ when 221-HLA-B*57:01 cells were pre-treated with TUN. These data 
indicates that N-glycosylation of HLA-B*57:01 plays a critical and functional role in 
KIR3DL1 binding and can modulate NK cell function, a finding that may extend to other 
KIR:HLA interactions that have not yet been studied in the context of N-glycolysation. 
 
6.3.2 This study uniquely describes N-glycan dependency in KIR:HLA 
interactions, and refutes prior studies 
Reports of the importance of N-glycosylation for KIR:HLA binding are scarce, 
save for one study suggesting that the HLA-I N-glycan does not influence KIR 
binding139. In contrast, several studies reported the consequences of HLA-I N-
glycosylation modifications on T-cell receptor (TCR) binding115,140–142.  Those reports all 
concluded that TCR binding to HLA-I (and MHC class I in mice) is independent of HLA-I 
glycosylation, given the relatively long distance between the TCR binding site and the 
HLA-I N86 glycan. KIR:HLA crystal structures, however, reveal a very close proximity 
between the KIR binding site on HLA-I and position N86, which in these structures is 
aglycosylated due to the production of these proteins in E. coli (Illustration 6.1).  This 
suggests that the HLA-I N86 glycan may be contacting KIR and influencing binding 
avidity. Of note, the one study that concluded that HLA-I glycosylation was not 
necessary for KIR binding was based on a generally assumed interaction between HLA-
B*08:01 and an undiscovered inhibitory KIR, which later was found to be the effects of 
the interaction between the inhibitory receptor NKG2A and HLA-E, which was not 
discovered at the time of the study143. Thus, to the best of our knowledge, our study is 
the first to implicate the HLA-I N-glycan as being critical for KIR:HLA binding, which may 
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serve as another means of modulating the interaction between NK cell receptors and 
target cell ligands.  
 
Illustration 6.1: N86 site on crystal structure of KIR3DL1 binding to HLA-B*57:01. KIR3DL1 (red) is 
shown binding to HLA-B*57 (green) complexed to β2-microglobulin (β2m; blue-gray) and presenting the 
LF9 peptide (magenta). Asparagine at position 86 (N86), the site of HLA-I N-glycosylation, is indicated 
from side view (a) and top view (b). Images were generated using PyMOL (DeLano Scientific LLC) based 
on the structure published in 24. 
 
 
 
6.3.3 HIV-1 may alter KIR:HLA interactions by modifying N-glycans as an 
immune evasion tactic 
It has been demonstrated that the glycosylation pattern of several immune 
receptor-ligand pairs can be influenced in the setting of infection. In HIV-1 infection, a 
global shift in the glycosylation pattern of IgG has been observed, with HIV-1-specific 
antibodies displaying the most distinct glycosylation patterns144,145. This shift in IgG 
glycosylation patterns can alter Fc receptor binding and is associated with improved 
antiviral activity and control of HIV-1, but has also been described for other viral and 
HLA-B*57:01
KIR3DL1*001
β2m
N86
LF9
N86
a            b 
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bacterial infections144,146. Indeed, the N-glycan structure found on IgG is very similar to 
the HLA-I N86 glycan, and can be modified similarly by the addition of fucose, bisecting 
N-acetyl glucosamine, galactose, or sialic acid110,147,148. Furthermore, HIV-1 infection 
has been shown to alter glycosylation in host cells149, with its envelope protein in 
particular incorporating an unusually large amount of high-mannose N-glycans150. Thus, 
it is conceivable that HIV-1 might affect HLA-I glycosylation, either as a host response 
mechanism or a direct immunevasive tactic depending on whether HLA-I binding to NK 
cell receptors is enhanced or diminished by the altered glycosylation pattern. It has 
been suggested that other viruses have taken advantage of this level of regulation, as in 
the case of hepatitis C virus, which downregulates HLA-I expression by inhibiting N-
glycosylation in order to escape immune recognition151. 
While much about the role of modified glycosylation patterns remains to be 
elucidated, our data demonstrates the importance of glycosylation in KIR:HLA binding 
and that removal of the glycan has a functional effect on the activation of NK cells. The 
extent to which pathogens and the immune system can exploit this mechanism to their 
advantage or whether this mechanism can be harnessed for therapeutic purposes 
remains to be determined. 
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Supplementary Figure S2.1: Complex conformation and β2m content assessment of non-classical 
HLA-I-coated beads. Non-classical HLA-I-coated beads (generated in this study) were untreated or acid-
pulsed and stained with (a) anti-pan-HLA-I complex antibody (clone: W6/32) to assess for complex 
conformation on beads and (b) anti-β2m antibody to quantify β2m content. 
 
 
  
a             b 
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Supplementary Figure S2.2: HLA-I OC generation after acid pulsing. Indicated cell lines were stained 
with anti-HLA-I complex (W6/32) antibody and anti-HLA-B,C OC (HC10) antibody to confirm OC 
generation after acid pulsing protocol. 
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Supplementary Figure S2.3: 721.221 HLA transductants triggering of KIRζ Jurkat reporter cells. 
KIR3DL1ζ (green bars), KIR3DS1hiζ (red bars), and untransduced (white bars) Jurkat reporter cells were 
co-incubated with untreated (-) or acid pulsed (+) 721.221 cells expressing the indicated HLA-I proteins 
(2.5-h incubation and reporter:target cell ratio of 1:10); reporter activity was measured as the percentage 
of CD69+hi Jurkat reporter cells. Data represent n = 3 technical replicates; independent experiments were 
performed for each 721.221 HLA transductant co-incubated with each Jurkat reporter cell line (n = 2 – 5; 
data not shown). 
 
 
 
  
Jurkat reporter cell: untransduced KIR3DL1ζ KIR3DS1hiζ
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Supplementary Figure S2.4: HLA-F-deficient cell lines do not trigger KIR3DS1hiζ Jurkat reporter 
cells. KIR3DL1ζ (top right panel), KIR3DS1hiζ (bottom left panel), KIR3DL2ζ (bottom right panel), and 
untransduced (top left panel) Jurkat reporter cells were co-incubated with untreated (–; black bars) or 
acid-pulsed (+, gray bars) cell lines (2.5-h incubation and reporter:target cell ratio of 1:10); reporter 
activity was measured as the percentage of CD69+hi Jurkat reporter cells. Cell lines used were EL-4 cells 
(mouse T-lymphoblastoid cell line), K562 cells (human chronic myelogenous leukemia line), and THP-1 
cells (human acute monocytic leukemia line), all of which do not express HLA-F. 
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Supplementary Figure S3.1: NK-cell clone phenotypes for plate-bound ligand assay. NK-cell clones 
used for plate-bound ligand assays were stained for various NK-cell receptors, as indicated; KIR2Ds was 
measured by staining with anti-KIR2DL2/L3 (clone: DX27) and anti-KIR2DL1/S1 (clone: HP-MA4) having 
the same fluorophore. 
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Supplementary Figure S3.2: KIR3DS1+ NKCLs have superior intrinsic antiviral cytokine production 
capacity. KIR3DS1+ (red dots) and KIR3DS1– NKCLs (black dots) were seeded onto well plates coated 
with irrelevant protein (neg. ctrl), human IgG (hIgG), or anti-NKp46 + anti-CD2 antibodies (α-NKp46+α-
CD2). NKCLs were incubated for 5 h with anti-CD107a fluorescent antibody and brefeldin A, followed by 
surface stain for NK-cell markers and intracellular cytokine stain for IFN-γ, TNF-α, and MIP-1β (for details, 
see Materials and Methods). The raw percentages of CD107a+ (top left panel), IFN-γ+ (top right panel), 
TNF-α+ (bottom left panel), and MIP-1β+ (bottom right panel) NKCLs are presented. One-way ANOVA 
with Sidak multiple comparisons test comparing select columns was performed, and all statistically 
significant differences are presented (*, **, and *** denotes, p < 0.05, < 0.01, and < 0.001, respectively). 
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Supplementary Figure S3.3: Anti-HLA-F antibody (clone: mAbcam 8224) Western blot specificity 
testing. Cell lysates (non-nuclear) from cell lines were run on reducing/denaturing SDS-PAGE, followed 
by immunoblotting for HLA-F and β-actin (loading control) (for further details on immunoblotting, see 
Materials and Methods). In a, Jurkat cells (HLA-F–) and 721.221 cells (HLA-F+) were compared. In b, 
untransduced (UT) THP-1 cells (HLA-F-deficient) and THP-1 cells transduced with N-terminally FLAG-
tagged HLA-F were compared. In c, untransduced (UT) Jurkat cells and Jurkat cells transduced with N-
terminally FLAG-tagged HLA-F were compared. 
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Supplementary Figure S3.4: Quality control testing of HLA-F mRNA probes in HLA-F+ and HLA-F– 
cell lines. Fluorescent in situ hybridization and flow cytometry was done on an HLA-F+ cell line (BCL) and 
an HLA-F– cell line (Jurkat cells) with probes for HLA-F mRNA and also RPL13a mRNA (a housekeeping 
gene). Dotted histograms indicate staining without probes (‘– probe’; negative control) and solid-line, filled 
histograms are staining with probe (‘+ probe’). 
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Supplementary Figure S3.5: NK-cell clone phenotypes for co-culture assay. NK-cell clones used for 
HIV-1 replication inhibition assays were stained for various NK-cell receptors. ‘+’ denotes >90% 
expression of the indicated receptor, ‘–’ denotes a frequency of <5%, and ‘+/–’ denotes a frequency >5% 
(in both cases for #0, ~10%). 
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Supplementary Figure S3.6: Low-temperature incubation potently mobilizes HLA-F to the cell 
surface. Jurkat-HLA-FFLAG cells (transduction efficiency ~10%) were cultured under normal conditions 
(37°C and 5% CO2) or incubated at 26°C (and 5% CO2) for 18 h. Cells were subsequently stained with 
anti-FLAG antibody to assess cell-surface expression of HLA-F. 
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Gene 
Symbol Description 
CRISPR 
Score 
EXT1 exostosin glycosyltransferase 1 7.047 
UXS1 UDP-glucuronate decarboxylase 1 (a.k.a. UDP-xylose synthase 1) 4.9493 
EXTL3 exostosin-like glycosyltransferase 3 4.394 
UGDH UDP-glucose 6-dehydrogenase 4.0326 
PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1.1497 
EXT2 exostosin glycosyltransferase 2 0.7124 
B3GAT3 beta-1,3-glucuronyltransferase 3 0.6418 
XYLT2 xylosyltransferase 2 0.4728 
B4GALT7 xylosylprotein beta 1,4-galactosyltransferase 7 -0.4949 
 
Supplementary Table S4.1: Genome-wide CRISPR/Cas9 knock-out screen top hits. Top nine 
enriched genes (symbol and description) are presented with their determined CRISPR score. 
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Supplemental Figure S5.1: Titration of glycosylation inhibitors. The effect of co-incubating 721.221-
HLA-B*57:01 cells with different concentrations of TUN (in a) and CSP (in b) on the expression of CD69 
in KIR3DL1ζ
+
 Jurkat cells (n = 1 for each). Reporter assay was carried out for 2 h at a reporter-to-target 
cell ratio = 10:1. 
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